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Abstract  
 
The phagocytic clearance of apoptotic cells –efferocytosis- is essential for maintaining 
immune homeostasis. Uncleared apoptotic cells can undergo secondary necrosis releasing 
endogenous danger signals such as high mobility group box protein 1 (HMGB1) into the 
extracellular milieu, triggering the innate immune system. Kidney Injury Molecule -1 
(KIM-1) is a phosphatidylserine (PS) receptor that has been shown to confer on proximal 
tubular epithelial cells (PTECs) the ability to clear apoptotic cells during acute kidney 
injury. KIM-1 is overexpressed by various human tumours including renal clear cell 
carcinoma (RCC), though the impact of this on tumour progression is not known. 
Importantly, RCC tumours are highly resistant to chemotherapies and radiotherapies that 
are known to concurrently induce tumour cell apoptosis and trigger an immune response 
to the dying cancer cells. In this thesis I show, for the first time, that endogenous KIM-1 
expressed by human RCC cell lines enables them to become semi-professional 
phagocytes and efficiently engulf apoptotic and necrotic cells. Using siRNA-mediated 
knockdown of KIM-1 expression in RCC cells, we show that KIM-1-dependent 
phagocytosis by RCC cells significantly reduced the leakage of HMGB1 from apoptotic 
cells undergoing secondary necrosis or necrotic cells. In addition, we demonstrate that the 
failure to clear dying cells by RCC cells was associated with enhanced activation of 
primary dendritic cells when they were exposed to the conditioned medium from RCC 
cells fed apoptotic or necrotic cells. Therefore, we propose that the upregulation of KIM-
1 expression by cancers may allow them to evade the immune system and immunogenic 
cell death by chemotherapy thereby making KIM-1 a potential therapeutic target.  
 
Key Words: KIM-1, cancer, HMGB1, danger signals, efferocytosis, immune 
surveillance, renal cell carcinoma, RT-PCR, apoptosis, Western Blot, Flow cytometry  
 
 
	  	   iii	  
Dedications 
 
I dedicate this thesis to my parents who through all the ups and downs in the past three 
years have served as my motivators, advisors and strongest supporters. Without you both 
I never would have made it this far, learned the value of failure and the importance of 
cherishing the successes. You taught me to aim as high as I could imagine but never to 
lose sight of what I was aiming for.  
 
I also dedicate this to my sister whose wisdom, beyond her years, reminded me that this 
was only one chapter of many to come. From a young age you taught me how to stand up 
for myself, to not hide from my potential and as you always said “the power of positive 
thinking”. You are my rock and for that I am eternally grateful. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Character cannot be developed in ease and quiet. Only through experience of trial and 
suffering can the soul be strengthened, ambition inspired, and success achieved.” 
- Helen Keller 
	  	   iv	  
Acknowledgements  
 
 
I would like to express my gratitude and appreciation towards my supervisor Dr. 
Gunaratnam for his support and guidance over the last three years. His willingness to 
teach in conjunction with his dedication has taught me to think analytically, fostering a 
genuine appreciation for science.  
I would also like to thank Dr. Bhagirath Singh and Dr. Bryan Heit for sitting on my 
advisory committee and for steering me in the right direction as needed.  
I would like to thank all the members, past and present, of the Gunaratnam lab for their 
support and encouragement. I would like to say a special thanks to Dr. Xizhong Zhang 
for teaching me how to do cell culture and for appreciating that patience is a virtue. I am 
also indebted to Ola Ismail for the training she provided me upon my arrival to the 
laboratory and to this date. Finally the undergraduates, new graduates, and medical 
students I interacted with over the course of my Masters, I look forward to witnessing 
your successes in the future.  
Lastly, I would like to acknowledge the many friends and peers I have met here at the 
University of Western Ontario, you made this experience a truly memorable one.  
 
 
 
 
 
 
 
 
 
 
 
	  	   v	  
Table of Contents 
ABSTRACT ...................................................................................................................... II 
DEDICATIONS .............................................................................................................. III 
ACKNOWLEDGEMENTS ........................................................................................... IV 
LIST OF TABLES ....................................................................................................... VIII 
LIST OF FIGURES ........................................................................................................ IX 
LIST OF APPENDICES ................................................................................................. X 
ABBREVIATIONS ......................................................................................................... XI 
CHAPTER 1:INTRODUCTION ..................................................................................... 1 
1.1.0 THE HALLMARKS OF CANCER ................................................................................. 1 
1.1.1 Sustained Proliferative Signalling ..................................................................... 1 
1.1.2 Avoiding Growth Suppressors ........................................................................... 2 
1.1.3 Resisting Cell Death .......................................................................................... 3 
1.1.4 Angiogenesis ...................................................................................................... 4 
1.1.5 Activating invasion and metastasis .................................................................... 4 
1.1.6 Enabling Replicative Immortality ...................................................................... 5 
1.1.7 Enabling Characteristic: Genome Instability and Mutation ............................. 5 
1.1.8 Enabling Characteristic: Tumour Promoting Inflammation ............................. 6 
1.1.9 An Emerging Hallmark: Reprogramming Energy Metabolism ......................... 6 
1.1.10 An Emerging Hallmark: Evasion from Immune Destruction .......................... 7 
1.2.0 THE CANCER IMMUNOSURVEILLENCE THEORY ........................................................ 7 
1.3.0 FROM IMMUNE SURVEILLANCE TO IMMUNE EDITING ............................................... 9 
1.4.0 THE THREE PHASES OF CANCER SURVEILLANCE ...................................................... 9 
1.5.0 EFFEROCYTOSIS .................................................................................................... 11 
1.6.0. IMMUNOGENIC CELL DEATH ................................................................................. 11 
1.7.0 ADJUVANT ROLE FOR CELL DEATH DURING CHEMOTHERAPY OF CANCER .............. 12 
1.8.0 DYING CELLS TRIGGER STERILE INFLAMMATION ................................................... 13 
1.9.0 HIGH MOBILITY GROUP BOX-1 (HMGB1) ........................................................... 13 
1.10.0 PROFESSIONAL VS. NON-PROFESSIONAL PHAGOCYTES ....................................... 16 
	  	   vi	  
1.11.0 THE POST-PHAGOCYTIC RESPONSE ..................................................................... 17 
1.12.0 THE THREE SIGNALS OF TUMOUR TARGETING .................................................... 18 
1.12.1 “Eat-Me Signals” .......................................................................................... 18 
1.12.2 “Don’t Eat-Me Signals” ................................................................................ 19 
1.12.3 “Come-and-Get-Me Signals” ........................................................................ 23 
1.13.0 KIDNEY INJURY MOLECULE-1 ............................................................................. 23 
1.14.0 RENAL CELL CARCINOMA ................................................................................... 25 
1.15.0 KIM-1 IS EXPRESSED BY MANY HUMAN CANCERS ............................................... 26 
1.16.0 FOUNDATIONAL WORK AND THESIS RATIONALE ................................................ 27 
1.16.1 Foundational Work ........................................................................................ 27 
1.16.2 Thesis Rationale ............................................................................................. 30 
CHAPTER 2: MATERIALS AND METHODS .......................................................... 34 
2.1.0 CELL CULTURE ..................................................................................................... 34 
2.2.0 PLASMID TRANSFECTION ...................................................................................... 36 
2.3.0 THYMOCYTE CULTURE AND INDUCTION OF APOPTOSIS OR NECROSIS .................. 36 
2.4.0 RNA EXTRACTION ................................................................................................ 37 
2.5.0 COMPLEMENTARY DNA (CDNA) SYNTHESIS ....................................................... 37 
2.6.0 QUANTITATIVE REAL TIME PCR (QRT-PCR) ....................................................... 37 
2.7.0 KIM-1 SIRNA KNOCKDOWN ................................................................................ 39 
2.8.0 WESTERN BLOT PROCEDURE ................................................................................ 39 
2.9.0 DENDRITIC CELL CULTURE ................................................................................... 42 
2.8.0 DENDRITIC CELL MARKER STAINING ................................................................... 42 
2.10.0 KIM-1 SURFACE STAINING ................................................................................. 42 
2.11.0 ANNEXIN V/PI STAINING AND ANALYSIS ............................................................ 42 
2.12.0 ANIMALS ............................................................................................................. 45 
2.13.0 STATISTICAL ANALYSES ..................................................................................... 45 
CHAPTER 3.0 RESULTS .............................................................................................. 46 
3.1 CHARACTERIZING THE EXPRESSION KIM-1 IN HUMAN CANCERS ............................. 46 
3.2 KIM-1 EXPRESSION IS REQUIRED FOR PHAGOCYTOSIS ............................................. 51 
3.3 KIM-1 IS REQUIRED FOR RCC- PHAGOCYTOSIS OF APOPTOTIC AND NECROTIC CELLS
....................................................................................................................................... 62 
	  	   vii	  
3.4 HMGB1 IS RELEASED FROM APOPTOTIC AND NECROTIC CELLS ............................... 70 
3.5 ASSESSING THE STATUS OF HMGB1 IN THE MEDIA POST PHAGOCYTOSIS ................ 73 
CHAPTER 4: DISCUSSION ......................................................................................... 86 
4.1.0 OVERVIEW ............................................................................................................ 86 
4.2.0 IDENTIFICATION OF KIM-1 IN HUMAN CANCERS ................................................... 89 
4.3.0 KIM-1 EXPRESSION CONFERS ON RCC CELLS THE ABILITY TO PHAGOCYTOSE 
APOPTOTIC AND NECROTIC CELLS. ................................................................................. 91 
4.4.0 KIM-1-EXPRESSING CANCER CELLS SEQUESTER HMGB1 RELEASE BY APOPTOTIC 
AND NECROTIC CELLS VIA PHAGOCYTOSIS ..................................................................... 94 
4.5.0 KIM-1 EXPRESSION MAY HELP CANCER CELLS EVADE THE INNATE IMMUNE 
RESPONSE TO APOPTOTIC AND NECROTIC CANCER CELLS ............................................... 97 
4.6.0 FUTURE DIRECTIONS ............................................................................................. 97 
4.7.0 IMPLICATIONS ....................................................................................................... 98 
REFERENCES ................................................................................................................ 99 
APPENDICES ............................................................................................................... 116 
CURRICULUM VITAE ............................................................................................... 124 
 
 
  
	  	   viii	  
List of Tables 	  
Table 2.1 Cell lines, growth conditions and sources………..………………………..... 34 
Table 2.2 Human primers used for RT-PCR ………………………………...…………38 
Table 2.3 Primary and secondary antibodies for western blot…...…………………….. 41 
Table 2.4 Cellular markers used in flow cytometry analysis ……………………...……44 
	  	   ix	  
List of Figures  
 
Figure 1.1 The pro-inflammatory effects and results of HMGB1 release 
……………….15  
Figure 1.2 The result of CD47 expression on tumour cell survival………………...……22 
Figure 1.3 KIM-1 expression prevents the leakage of HMGB1 from apoptotic cells…...29 
Figure 1.4 Hypothetical system………………...………………………………………..32 
Figure 3.1 Comparison of KIM-1 expression on various cancers……………………….48 
Figure 3.2 Surface staining for KIM-1 on 769P and 786-0 cells…….………………….50 
Figure 3.3 Characterization of live, apoptotic and necrotic thymocytes………....……...53 
Figure 3.4 Surface staining for human KIM-1 on KIM-1 negative and KIM-1 positive 
cells………………………………………………………………………………………57 
Figure 3.5 KIM-1 expression enhances the phagocytosis of apoptotic and necrotic 
cells………………………………………………………………………………………59 
Figure 3.6 Representative trend in the phagocytosis of live, apoptotic and necrotic 
cells………………………………………………………………………………………61 
Figure 3.7 769P cells engulf both apoptotic and necrotic cells………………………….65 
Figure 3.8 Knockdown of KIM-1 in 769P cancer cells.....................................................67 
Figure 3.9 Change in phagocytosis of apoptotic and necrotic cells in KIM-1 siRNA 
treated cells………………………………………………………………………………69 
Figure 3.10 Passive leakage of HMGB1 from live, apoptotic and necrotic 
thymocytes……………………………………………………………………………….72 
Figure 3.11 Comparison in the passive leakage of HMGB1 as a result of KIM-1 
expression………………………………………………………………………………..76 
Figure 3.12 The sequestration of HMGB1 release into the media as a result of KIM-1 
expression………………………………………………………………………………..78 
Figure 3.13 KIM-1 expression reduced the activation of dendritic cells from PK1 
cells………………………………………………………………………………………82 
Figure 3.14 KIM-1 expression reduced the activation of dendritic cells from 769P 
cells……………………………………………………………………………………....84 
Figure 4.1 Implication of KIM-1 expression on tumour survival………………………..87 
	  	   x	  
List of Appendices  
 
Appendix I Structure of human KIM-1………………………………………………...117 
Appendix II Representative gating strategy for WT-PK1 and pcDNA-PK1 cells….….119 
Appendix III MFI for WT-PK1 vs. pcDNA-PK1 phagocytosis of apoptotic and necrotic 
cells……………………………………………………………………………………...122 
	  	   xi	  
Abbreviations  
 
Ab Antibody 
AKI Acute Kidney Injury  
AC Apoptotic Cells  
ANOVA Analysis Of Variance  
Bcl-2 B cell lymphoma-2 
BrdU Bromodeoxyuridine 
ccRCC clear cell Renal Carcinomas 
cDNA Complementary DNA 
CFSE Carboxyfluorescein Succinimidyl Ester 
DCs Dendritic Cells 
DEPC Diethylpyrocarbonate 
DMEM Dulbecco’s Modified Essential Medium 
EMEM Eagles Modified Essential Medium  
FACS Fluorescence Assisted Cell Sorting 
GAPDH Glyceraldehyde 3-phosphate 
Dehydrogenase 
GOH Geraniol 
G418 Geneticin  
HAVCR1 Hepatitis A Virus Cellular Receptor 1 
HRP HorseRadish Peroxidase  
IFN-γ Interferon gamma  
	  	   xii	  
IL-10 Interleukin-10 
IL-1β Interleukin-1β 
IL-6 Interleukin-6 
IRI Ischemia Reperfusion Injury  
KIM-1 Kidney Injury Molecule-1  
KIM-1 PK1/WT-KIM-1 LLC-KIM-1-PK1 
LKB1 Liver Kinase B1 
LPC Lysophosphatidylcholine 
MCP-1 Monocyte Chemoattractant Protein-1 
MDSC Myeloid Derived Suppressor Cells 
MFG-E8 Milk-fat-globule-EGF factor 8  
NEAA Non-Essential Amino Acids 
NC Necrotic Cells  
PBS Phosphate Buffered Saline  
pCDNA-PK1 LLC pcDNA-PK1 
PFA Paraformaldehyde  
PMN Polymorphonuclear leukocytes 
P/S Penicillin Streptomycin  
PS Phosphatidylserine  
RCF Relative Centrifugal Force  
RB Retinoblastoma  
RNA Ribonucleic Acid 
RCC Renal Cell Carcinoma  
	  	   xiii	  
SDS Sodium Dodecyl Sulfate 
SEM Standard Error of Mean 
SIR Sterile Inflammatory Response 
SIRPα Signal regulatory protein α 
qRT-PCR Quantitative Real Time Reverse 
Transcription-Polymerase Chain Reaction 
TAM Tumour Associated Macrophage 
TCE Tricholoethylene 
TGF-β Transforming Growth Factor Beta 
TIL Tumour Infiltrating Lymphocytes 
TSP-1 Thrombospondin-1  
TNF-α Tumour Necrosis Factor Alpha 
Tx/Thy Thymocytes 
uKIM-1 Urinary KIM-1 
UV Ultraviolet 
VEGF-A Vascular Endothelial Growth Factor-A 
1	  
	  
Chapter 1:Introduction 
1.1.0 The Hallmarks of Cancer  
 
The simplest descriptor of a tumour is a grouping of transformed host cells with an 
accumulation of genetic and epigenetic aberrations[1]. Beyond that, the simplicity of the 
definition is replaced by the true and complex nature of tumour formation, sustenance 
and survival. Within the same host, tumour cell populations display a high degree of 
heterogeneity[2]. Studies have shown that biopsy samples taken from the time of primary 
specimen collection to metastasis were highly dissimilar. Additionally a study by the 
Sanger group on the profile of renal carcinoma sites demonstrated that some molecular 
transformations were only present at primary and metastatic sites and not uniformly 
throughout all tumour colonies[3]. While the inherent complexity of tumour masses 
became more apparent, researchers noticed fundamental characteristics that enabled 
tumours to progress.  
 
In 2000, Hanahan and Weinberg introduced and coined these collective traits, “the 
hallmarks of cancer”. The hallmarks served as a characteristic framework for neoplastic 
diseases. The six hallmarks of cancer; sustained proliferative signalling, avoiding growth 
suppressors, resisting cell death, angiogenesis, activating invasion and metastasis and 
enabling replicative immortality, were considered independent yet complementary, and 
form the foundation for cancer development. In 2011 Hanahan and Weinberg amended 
their hallmarks to include two burgeoning characteristics that reflected the progress in 
cancer research over the last decade. The six hallmarks introduced culminated in the 
recognition that the tumour microenvironment played a significant role in successful 
cancer establishment.  
 
1.1.1 Sustained Proliferative Signalling  
 
The ability to deregulate the cell cycle is considered the most fundamental attribute of 
cancer cells. This process allows for the development of neoplasms and ultimately 
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metastases due to their rapid cellular proliferation[4]. The origin of the growth signals 
that serve to sustain proliferation are under-characterized to date. Studies have 
highlighted the ability for both the tumour and nearby non-tumour cells to supply cancers 
with growth signals[5, 6]. Characteristics for increased growth signalling include the 
upregulation of growth receptors on tumour cells, constitutive activation of growth 
pathways[7] and paracrine signalling[8]. Research has also shown the propensity of 
cancers to disrupt negative feedback loops that attenuate proliferation[9, 10] and the 
induction of cell senescence to avoid detection by the immune system of erratic growth 
patterns[11].  
 
1.1.2 Avoiding Growth Suppressors  
 
Part in parcel with sustaining a tumours’ proliferative capabilities, exists the need to 
avoid growth suppressors. Through various gain or loss of function experiments in mice, 
proteins whose sole functions are to suppress tumours have been identified. The tumour 
suppressor protein p53 is perhaps the most well researched protein in cancer[12]. It 
determines if cells should become apoptotic, proliferate or become senescent[13]. The 
absence of p53 is prevalent across many human cancers and permits persistent cell 
proliferation[12, 14]. Further support for the necessity to evade growth suppressors stems 
from the ability of cancers to overcome the effects of contact inhibition. Contact 
inhibition occurs when cell division is halted as a result of high cellular density[15]. 
Under normal conditions, cells will stop proliferating and form a monolayer. Contact 
inhibition has been shown to be an anticancer mechanism mediated by cell surface 
proteins[16]. Inactivation of proteins involved in cell-structure[17, 18] result in 
multilayered three-dimensional structures characteristic of tumours[19, 20]. One example 
is liver kinase B1 (LKB1), a serine threonine kinase that is characterized as a tumour 
suppressor gene and is inactivated in certain human malignancies[21, 22]. LKB1 
inactivation enhances STAT3 signalling, which results in tumour cell proliferation, in 
both lung and thyroid cancers [23, 24].  
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1.1.3 Resisting Cell Death  
 
Apoptosis serves as the primary means to limit tumourigenesis, as established by studies 
examining the death pathways in cancers[25]. When cancer cells undergo stress, such as 
chemotherapy, various pro-apoptotic or anti-apoptotic genes are upregulated to induce 
cancer cell apoptosis [26, 27]. Therefore tumours have developed a way to circumvent 
apoptotic death in order to allow for the development of less immunogenic tumours. One 
highly manipulated apoptotic pathway in cancer is the signal B cell lymphoma-2 (Bcl-2) 
protein family. In the presence of cellular damage or stress, the pro-survival signal Bcl-2 
becomes inactivated. Downstream effectors such as Bax and Bak then make the outer 
mitochondrial membrane permeable, releasing cytochrome c. As a result of cytochrome c 
release, caspase 9, as well as other caspases, become activated resulting in cell 
apoptosis[28]. The overexpression of Bcl-2 protein has also been associated with 
increased resistance to chemotherapy in various human cancers[29]. As a result, the 
inhibition of Bcl-2’s pro-survival function is being used a potential chemotherapeutic 
target[30].     
 
Autophagy is a mechanism that has come to light as a potential tumour enabler. For the 
most part autophagy occurs basally at low levels and is induced in instances of cell stress 
such as nutrient deficiencies[31]. This process, mediated by autophagosomes, allows for 
the breakdown of cellular organelles in order to recycle catabolites for energy metabolism 
and biosynthesis. The process is characterized by the degradation of cytoplasmic 
macromolecules and organelles[32-35]. Studies have shown a correlation between 
autophagic activation and cancer progression in the early stages of development[36]. 
However, various groups have noted either pro-cancer or anti-cancer outcomes of 
autophagy, leaving its influence up for debate[37]. Radiotherapy and nutrient starvation 
in the form of chemotherapeutic treatments have been shown to have a cytoprotective 
role in cancer cells and even allow cancer cells to regress to a state of reversible 
dormancy due to autophagy. 
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1.1.4 Angiogenesis   
 
Solid tumours require oxygen and nutrients to survive. Tumours also need to effectively 
remove waste products, toxins and carbon dioxide that could potentially impede growth.  
Angiogenesis is the process whereby new tumour blood vessels spring from established 
vasculature. [38]. One well-known angiogenesis promoting factor is vascular endothelial 
growth factor (VEGF-A). VEGF-A expression is upregulated in the early stages of cancer 
formation[38-41]. As tumours grow and nutrient sources become limited, the inner mass 
becomes the most isolated from nutrients and oxygen resulting in tumour hypoxia. The 
induction of hypoxic signalling in the inner mass via hypoxia-inducible factors results in 
VEGF-A production[42, 43]. VEFG-A expression has been shown to increase tumour 
survival by allowing for the migration of tumours to new sites abundant in resources[44-
46]. The importance of angiogenesis to solid tumour progression is underscored by the 
myriad of anti-angiogenic therapies that have been developed and are being tested in 
patients[47, 48]. 
 
 
1.1.5 Activating invasion and metastasis  
 
One nearly universal feature of human solid tumour cells is the loss of E-cadherin 
expression. E-cadherin helps to form junctions with adjacent epithelial cells, resulting in 
fixed monolayers without migratory capabilities. The high frequency of E-cadherin gene 
inactivation or protein downregulation alluded to it being a key contributor to cancer 
survival[49, 50]. As a result this process was termed the “invasion-metastasis 
cascade”[51] based on a schema of discrete steps that results in multiple macroscopic 
tumours throughout the body[52]. Other pro-invasion and metastatic genes manipulated 
by cancers include the transcription factor involved in cell proliferation and 
differentiation HOXB9, matrix metalloproteases MMP-2 and MMP-8[53] and breast 
tumour kinase (BRK) which is a cell migratory factor, to name a few[54].  
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1.1.6 Enabling Replicative Immortality  
 
In order to grow, it is understood that cancer cells require unlimited replicative 
capacity[55, 56]. One agent implicated in immortalizing cells is telomerase. Telomerase 
is a specialized DNA polymerase that adds telomere repeats to the end of DNA to 
prolong life span. The necessity for telomerase in cancers has been demonstrated by its 
silencing, resulting in cancer cells becoming senescent as opposed to developing into 
functional cancer cells [57]. Recent research has detailed an interesting role for 
telomerase, where its expression in premalignant lesions is not observed, yet its function 
is enhanced in established tumours[58, 59]. Researchers hypothesize that delayed 
acquisition of telomerase expression serves as a means for tumours to generate tumour-
promoting mutations and once established, enhanced telomerase activation stabilizes the 
mutated genome to allow for unlimited replication of cancer cells [4]. As a result, 
tumours have developed a calculated mechanism to ensure their survival.  
 
 
1.1.7 Enabling Characteristic: Genome Instability and Mutation  
 
The acquisition of many of the hallmarks discussed thus far is dependent on genomic 
instability and the acquisition of mutations in various genes and pathways to produce the 
tumourigenic phenotype. A substantial number of mutations are not only heritable but 
epigenetic, meaning methylations and histone rearrangements can induce 
mutagenesis[60]. In the process of acquiring the series of mutant genes needed to 
orchestrate tumourigenesis, cancer cells often increase their rates of mutation[61, 62] so 
that they can transform at an accelerated rate. The ability to increase mutation rates, is 
often a result of tumour cells being sensitive to mutagenic agents as a result of these 
heritable changes, and so the cyclical nature of mutation acquisition influencing 
mutational rate increases until the tumour has outcompeted the immune system.  
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1.1.8 Enabling Characteristic: Tumour Promoting Inflammation  
 
In the last decade, a plethora of data was generated supporting the functionally important 
tumour-promoting effects that immune cells—largely of the innate immune system—
have on tumour progression[63-66]. This was first proposed by the finding in the early 
1970s that tumour growth could be promoted by macrophages found within the tumour 
environment[67]. Inflammation can contribute to tumour growth by; supplying growth 
survival factors that limit cell death, delivering extracellular matrix-modifying enzymes 
that promote angiogenesis, releasing factors that sustain proliferative signalling, and 
transporting pro-angiogenic, invasion and metastatic factors directly to the tumour.  One 
specific example is the finding that tumour localized macrophages tend to have a M2 
profile as opposed to an M1 profile[65]. M1 macrophages are associated with interferon 
gamma (IFN-γ), interleukin- 6 (IL-6) and interleukin -1β (IL-1β) production, and have 
been associated with tumour destruction[68]. In contrast M2 macrophages are associated 
with interleukin-4 (IL-4) and interleukin-10 (IL-10) production that drive tissue repair 
and remodelling after tissue injury through cellular division. It is postulated that M2 
macrophages can drive tumour progression[69, 70]. Furthermore, M2 macrophages 
promote the development of regulatory T-cells (Tregs) that are critical to the neutralization 
of effector cell-dependent killing of tumour cells (ex. CD8+ T-cell function) [71]. The 
identification of additional tumour promoting agents such as a myeloid derived 
suppressor cells (MDSCs) that can induce T-cell anergy and dendritic cell immaturity, 
brought attention to the role of inflammation in cancer survival.  
 
1.1.9 An Emerging Hallmark: Reprogramming Energy Metabolism  
 
A very under characterized hallmark that has not been explored much to this date is the 
role of reprogramming energy metabolism to sustain the growth and proliferation patterns 
seen within cancer cells. In 1930 Otto Warburg observed the switch cancers make to 
glycolysis as their primary metabolic process, even in the presence of oxygen[66]. The 
upregulation of various glucose transporters, such as GLU1, has been demonstrated in 
numerous cancers[72, 73]. Because of the relatively low ATP production associated with 
glycolysis relative to oxidative phosphorylation, it is elusive as to why cancers would 
7	  
	  
prefer this method.  
1.1.10 An Emerging Hallmark: Evasion from Immune Destruction 	  
The successful establishment of tumours in the presence of an ever-alert immune system 
implies that some tumour variants have successfully evaded immune destruction. The 
necessity for an intact and strong immune system to prevent tumour establishment was 
demonstrated in studies with patients who were immunodeficient. Though many of the 
cancers observed in these patients are caused by viruses such as lymphomas (Epstein-
Barr virus), Kaposi’s sarcoma (herpes viruses), and cervical cancer (human papilloma 
viruses), they are also at greater risk for malignancies where there is not a viral etiology 
such as cancers of the colon, lung, pancreas, kidney, head and neck, and non-melanoma 
skin cancers[74]. Patients with AIDS and recipients of solid organ transplants are at an 
increased risk of developing cancer due to their immunosuppressed status[75]. For 
example as a result of transplantation, patients are given immunosuppressive drugs to 
reduce the chances of organ rejection and increase the lifespan of organ function[76]. A 
review by the Cincinnati Transplant Tumour Registry from 1968 to 1995 found transplant 
patients had a two-fold greater risk of developing melanomas compared to healthy 
people[77]. Moreover, the University of Pittsburgh between 1980 and 1993 demonstrated 
that transplant patients were 25 times more likely to develop lung tumours than their 
healthy counterparts[78]. In combination with the plethora of data from studies in 
immunodeficient animal models, it is generally accepted that immunosuppressed or 
immunocompromised individuals have a higher propensity to develop cancers.   
 
1.2.0 The cancer immunosurveillence theory  
 
The concept of cancer immunosurveillence was first developed in the early 1900s by Paul 
Ehlrich who proposed that the body could suppress an “overwhelming frequency” of 
carcinomas[79]. For the most part of the twentieth century however, due to the infancy of 
the field of immunology, this concept was not appreciated. Approximately 50 years later, 
the discovery of tumour antigens served as the cornerstone of the immune surveillance 
hypothesis established by Sir Macfarlane Burnet and Lewis Thomas in 1957[80]. The 
immune surveillance theory is defined below:  
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“In large, long-lived animals, … inheritable genetic changes must be common in somatic 
cells and a pro- portion of these changes will represent a step toward malignancy. It is 
an evolutionary necessity that there should be some mechanism for eliminating or 
inactivating such potentially dangerous mutant cells and it is postulated that this 
mechanism is of immunological character.” Sir Macfarlane Burnet and Lewis Thomas ([80]) 
The immediate corollary of the immunosurveillence theory was that immunodeficient 
individuals would have a higher incidence of spontaneous induced tumours, and that the 
agent of recognition and elimination were lymphocytes. However, initially numerous 
studies determined that there was no difference in tumour formation or latency period 
after injection with the various carcinogens such as methycholanthrene (MCA) into mice. 
[81-85]. As a result of the lack of appreciation of NK T-cells (NK) in nude mice profiles 
[86, 87], and the infancy of the field of immunology (ex. poorly designed studies), the 
immune surveillance theory was not fully appreciated until the early 2000s [88, 89].  
 
During the late 1990s, as the potential and reach of immunology grew, two key findings 
relit the interest in the concept of cancer immunosurveillence. The first was the role of 
interferon gamma (IFN-γ) in the protection of the host against transplanted and 
chemically induced tumours[90]. The second was the discovery that C57BL/6 mice 
lacking perforin were more prone to tumour formation than their wild type 
counterparts[91, 92]. As a result, attention was redirected back towards the differences 
between immune competent and immune deficient hosts in tumour development.  
 
The importance of NK, T-cell and B-cell function in tumour establishment was 
demonstrated using recombination activating gene-1 (RAG-1) and RAG-2 knockout 
mice. Mice lacking RAG-1 or RAG-2 cannot undergo rearrangement of lymphocyte 
antigen receptors, resulting in a lack of B-cells and T-cells[93, 94] and xenogenic 
tumours grown in these mice experienced prolonged tumour survival.  
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1.3.0 From immune surveillance to immune editing  
 
In 2001, seminal work by Schreiber and colleagues led to the realization that the immune 
system controls not only tumour quantity but also tumour quality (immunogenicity) 
prompting a major revision of the cancer immune surveillance hypothesis. Shankaran et 
al., found that tumours formed in immunodeficient mice, as a group, were more 
immunogenic than similar tumours derived from immune competent hosts ([95]). It was 
clear from the above studies that tumours grown in immunocompetent mice were 
qualitatively different from tumours grown in immunodeficient mice. The anti-cancer 
immune response thus functions as an effective extrinsic tumour-suppressor system. This 
observation led to the formulation of the cancer immunoediting hypothesis by Schreiber 
who later coined the term “cancer immunoediting”[96]. The notion that the immune 
system not only protects the host against tumour formation but also shapes tumour 
immunogenicity is the basis of the cancer immunoediting hypothesis, which stresses the 
dual host-protective and tumour-promoting actions of immunity on developing tumours. 
 
1.4.0 The three phases of cancer surveillance   
 
The cancer immunoediting theory is broken down into three components; elimination, 
equilibrium and escape[97]. The elimination phase encompasses the active component of 
the immune surveillance theory, whereby highly immunogenic tumours are eliminated 
without progressing to subsequent phases. Throughout the process, the immune system 
attempts to eliminate tumours through IFN-γ secretion and lymphocyte recruitment [98, 
99]. As solid tumours grow, their growth induces disruptions in the surrounding tissue 
resulting in the release of various inflammatory signals. The result is the recruitment of 
γδ T-cells, macrophages and dendritic cells into the site[100-102]. As a result, IFN-γ is 
produced, inducing cell apoptosis and direct tumour destruction[103]. Additionally 
chemokines (ex. IP-10, MIG, and I-TAC) produce anti-angiogenic effects leading to 
tumour starvation and elimination[104]. The third phase of the elimination process 
involves the recruitment of NK cells, macrophages, and tumour antigen specific CD4+ 
and CD8+ T-cells to the tumour site to successfully eliminate the most resistant 
components of the tumour[101, 105, 106].  During the elimination phase, innate and 
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adaptive immune cells have to not only discern between mutated and healthy cells, but 
also know where to find them. One way to discern and navigate is through the use of 
situational and chemotactic markers that can attract or repel both professional and non-
professional phagocytes. Theses cues are referred to as “eat-me”, “don’t- eat-me” and 
“come-get-me” or “find-me” signals which are discussed further at a later point.  
 
The equilibrium phase is reached when there is a balance between the immune response 
to the tumour and tumour survival. During this period, a form of Darwinian selection 
occurs, where immunogenic variants are eliminated and through the process of mutation, 
rare non-immunogenic forms are selected. If tumour cell destruction goes to completion, 
the elimination phase represents an endpoint of the cancer immunoediting process[98]. If, 
however, rare tumour cell variants survive the elimination phase, they enter the 
equilibrium phase in which the adaptive immune system prevents tumour cell outgrowth 
and also sculpts the immunogenicity of tumour cells. The equilibrium stage is considered 
the longest and may occur over a period of years where tumour may lay dormant while 
any outgrowth of occult tumours is specifically controlled by immunity[107]. The tumour 
may reside in patients for decades before being detected as either recurrence of the 
primary tumour or distant metastases.  
 
Finally, the escape phase results when the strength of the surviving tumour variants 
exceeds the capacity of the immune system to contain them and expand rapidly[107, 
108]. Conceivably, the selective pressure that promotes outgrowth of tumour cells is the 
result of acquired immunoevasive mutations or epigenetic changes. Potential mechanisms 
of immune evasion include increased resistance to the cytotoxic effects of immunity and 
down-regulation of major histocompatibility complex (MHC) class I proteins that result 
in the loss of antigen processing function[108]. At this point the tumour becomes 
clinically observable and may result in metastasis and the death of the host if untreated.  
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1.5.0 Efferocytosis 
 
Apoptosis, or programmed cell death, is a mechanism for eliminating damaged and dying 
cells and is crucial for maintaining tissue homeostasis in multi-cellular organisms[109]. 
The process of removing apoptotic cells through phagocytosis is referred to as 
efferocytosis[110]. Apoptosis occurs as a consequence of the turnover of cells following 
natural death, infection, tissue injury, and chemotherapy or radiotherapy of tumours. The 
specific recognition and ingestion of apoptotic cells is a highly conserved process 
throughout the body[111]. If not cleared rapidly, apoptotic cells can undergo secondary 
necrosis and release their pro-inflammatory intracellular contents into the surrounding 
tissue[112]. When released into the extracellular milieu, intracellular proteins such as 
high mobility group box 1 (HMGB1) can serve as danger associated molecular patterns 
(DAMPs) to trigger the innate immune response by signalling via pattern recognition 
receptors (e.g. Toll-like receptors) on cells of the innate immune system. DAMP 
molecules are normal cell- or extracellular matrix- components that are released by 
cellular injury or action of proteases at the site of tissue damage respectively[113]. 
Defects in apoptotic cell clearance mechanisms have been linked to autoimmunity and 
chronic inflammation[114]. While the removal of apoptotic cells is usually assigned to 
“professional” phagocytes such as macrophages and dendritic cells[115], efferocytosis is 
now known to occur in a large number of “non-professional” phagocytes including 
fibroblasts, endothelial cells and proximal renal tubular epithelial cells (PTECs)[116, 
117].  
 
1.6.0. Immunogenic cell death 
 
Apoptosis is largely regarded as an “immunologically silent” means of ridding the body 
of dying cells. The systemic injection of apoptotic cells has been reported by many to 
induce peripheral tolerance[118]. However, apoptotic cells are not always tolerogenic and 
can be immunogenic or “pro-inflammatory” for instance when virus-infected cells 
undergo apoptosis[119] or when some tumours are subjected to chemotherapy or 
radiotherapy[120, 121]. Therefore, a number of factors can determine if dying cells 
promote immunity or tolerance. Given that dendritic cells (DCs) play a central role in the 
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uptake of apoptotic cells and in the initiation of an immune response [122], it is not 
surprising that factors produced by dying cells can influence how dendritic cells promote 
tolerance or immunity[123]. Ideally, immunogenic cell death should be directed toward 
tumour cells and infected cells, whereas tolerogenic cell death should be associated with 
preventing unwanted immune responses to self.  
 
1.7.0 Adjuvant role for cell death during chemotherapy of cancer  
 
Emerging evidence suggests that cytotoxic chemotherapeutic agents such as 
anthracyclines work not by killing all cancer cells within a tumour but by eliciting an 
anticancer T-cell response triggered by chemotherapy-induced immunogenic cancer cell 
death[121, 124]. One requirement for dying cancer cells to elicit an immune response is 
the release of DAMPs, that mediate the maturation of DCs that have taken up the dead 
cells [123]. Certain forms of chemotherapy[120] and radiotherapy[124] can trigger 
immunogenic tumour cell death by causing dying cancer cells to release HMGB1, which 
interacts with Toll-like receptor 4 (TLR4) expressed by DCs[121, 124]. While the 
engulfed apoptotic cancer cell serves as a source of tumour antigen, the passive release of 
HMGB1 from dying cells is required for immunostimulatory presentation of antigen to 
anti-tumour CD8+ T-cells by dendritic cells (DCs). During chemotherapy or radiotherapy, 
DCs require signalling through TLR4 and its adaptor MyD88 for efficient processing and 
cross-presentation of antigen from dying tumour cells. Furthermore, chemotherapy likely 
produces more apoptotic tumour cells than the DC-clearance program can cope with, and 
thus are expected to proceed to secondary necrosis that can further result in HMGB1 
release.  The delayed clearance of apoptotic cancer cells may allow for enhanced cross-
presentation of intracellular antigens by mature dendritic cells [125]. Cancer cells, 
however, have evolved intricate mechanisms to evade T-cell-mediated killing such as 
MHC downregulation and induction of T-cell anergy. 
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1.8.0 Dying cells trigger sterile inflammation 
 
Injured or dying cells stimulate a sterile inflammatory response (SIR)[126] through 
collateral tissue damage from the inflammation[127-130]. This may be triggered in part 
by endogenous DAMPs that are released from cells that are distressed, damaged, or dying 
an abnormal death in order to alert the immune system [102, 130, 131]. Innate immune 
cells sensing and transducing inflammatory signals from injured cells initiate tissue 
damage by secreting pro-inflammatory mediators such as interleukin-1α (IL-1α)[130]. 
Mice deficient in certain Toll-like receptors or the IL-1R1 receptor (IL-1R), for instance, 
exhibit a markedly reduced SIR response and secondary tissue damage[130]. 
 
1.9.0 High Mobility Group Box-1 (HMGB1) 
 
HMGB1 is a 215 amino acid amphoterin, which is ubiquitously expressed and highly 
conserved through various cell types[132]. HMGB1 is a non-histone chromatin binding 
protein that serves to influence nuclear transcription and stabilize the genome[133, 134]. 
The release of HMGB1 from DNA can be done passively or actively following cellular 
injury and is therefore regarded to as a DAMP. The passive release of HMGB1 from 
necrotic cells has been characterized, though if the passive release of HMGB1 from 
apoptotic cells can occur is still highly debated[135, 136]. The active release of HMGB1 
mostly by monocytes and macrophages is used to amplify already existing pro-
inflammatory signals through its interaction with receptors such as the receptor for 
advanced glycation of end products (RAGE), TLR2 and TLR4[135, 137-139]. 
Interactions between HMGB1 and TLR4 have been demonstrated as necessary to induce 
a pro-inflammatory response, therefore characterizing HMGB1 as an alarmin[140]. 
Additionally HMGB1 release can be done in complex with nucleic acids which can also 
induce TLR signalling on macrophages and dendritic cells[141]  The diverse effects of 
HMGB1 release are summarized in Figure 1.1.  
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Figure 1.1 The pro-inflammatory effects and results of HMGB1 release. HMGB1 is a 
highly pro-inflammatory molecule, resulting in the activation and recruitment of 
macrophages, dendritic cells, T-cells and neutrophils to name a few. HMGB1 can be 
released either passively or actively from apoptotic and necrotic cells  
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Adapted from Ulloa et al., 2006[142] 
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Additionally, studies have shown the neutralization of HMGB1 results in decreased 
neutrophil and macrophage recruitment and increased damage in cardiovascular 
tissues[143]. As HMGB1 is ubiquitously expressed throughout the body it will act as a 
danger signal not only in specialized organs, but also throughout the body. In fact, 
increases in plasma/serum levels of HMGB1 have been reported in a wide spectrum of 
diseases including cerebral ischemia (stroke), appendicitis, arthritis, liver injury, and 
kidney injury[144-147]. 
 
The relationship between HMGB1 and cancer prognosis is still being elucidated. Studies 
have shown the integral role HMGB1 plays in inciting immune responses necessary for 
tumour destruction[148] whereas contrasting evidence exists for the role of HMGB1 in 
the metastasis and survival of various cancers. HMGB1 has been linked to the 
polarization of tumour associated macrophages (TAMs) to a M2-like cancer promoting 
phenotype, and has been correlated to lymph node metastasis in cervical squamous cell 
carcinomas (CSCC) indicating a potential tumour pro-survival role for HMGB1[149-
151].  
 
1.10.0 Professional vs. Non-professional Phagocytes 
 
Phagocytosis is an actin polymerization dependent uptake of large particles by cells 
known as phagocytes[152-154]. Molecules on the particles surface interact with receptors 
on the phagocyte either via direct or indirect (ex. opsonins) mechanisms[155]. Once eaten 
the cargo is degraded by the acidic and hydrolytically rich vesicles within the cell and 
processed by cellular machinery. Phagocytosis is the mechanism by which 
microorganisms and senescent cells are degraded, therefore being central to the hosts 
immune detection system[156, 157]. Professional phagocytes are primarily 
polymorphonuclear granulocytes (PMNs), monocytes, dendritic cells, primary 
macrophages or monocyte-macrophage like cell lines. Unlike non-professional 
phagocytes, professional phagocytes constitutively express phagocytic receptors, for 
example Fc receptors that bind to antibody coated particles, to trigger phagocytosis[158]. 
They move easily and quickly in response to chemotactic factors and can phagocytose 
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cargo at a rapid rate. Additionally they are strategically positioned within tissues or 
organs that filter blood and lymph, allowing for rapid movement and access to damaged 
sites in order to facilitate a quick immune response[159]. They also secrete mediators like 
radicals of oxygen and nitrogen, enzymes that degrade the extracellular matrix, cytokines, 
products stimulated by LPS, lipid mediators of inflammation and other agents that can 
modify the behaviour of phagocytes[160]. 
 
Non-professional phagocytes on the other hand include epithelial cells and 
fibroblasts[154, 161]. The distinction between non-professional and professional 
phagocytes beyond the lack of Fc receptors expression is the strengthened phagocytic 
response from professional cells. Unlike professional phagocytes, studies show that non-
professional cells take a significantly longer time to clear dying cells. However in the 
absence of professional phagocytes, non-professional cells are as effective as professional 
cells in clearing apoptotic and necrotic debris[162]. Furthermore, the range of particles 
which non-professional cells can consume is smaller than that of professionals due to 
their lack of diverse receptors. Non-professional cells cannot secrete microbial oxygen or 
nitrogen products and may not secrete cytokines beyond IFN-γ seen with 
fibroblasts[160]. 
 
1.11.0 The Post-Phagocytic Response 
 
The post-phagocytic response is characterized by numerous steps including but not 
limited to; the processing and presentation of antigen, the induction of tolerance or 
immune activation, and paracrine and downstream signalling [163]. Of particular 
importance is the alteration in the surrounding microenvironment and what this may 
mean in the context of cancers. Phagocytosis of apoptotic cells is coupled to the 
resolution of inflammation not only by limiting the release of noxious cellular contents, 
but also because apoptotic cell recognition or engulfment activates signals that suppress 
pro-inflammatory responses in the phagocyte[116, 118, 164-166]. Apoptotic cell 
recognition and/or engulfment by macrophages can promote release of IL-10, TGF-β, 
PAF, and PGE2 as well as the inhibition of TNF-α, CSF, IL-12, IL-1β, and IL-18 
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production[118, 167]. This anti-inflammatory response to apoptotic cell is not exclusive 
to professional phagocytes and may extend to epithelial cells [110, 168, 169].  
 
1.12.0 The Three Signals of Tumour Targeting  
 
While the adaptive immune response is recognized to play an important role in 
anti-tumour immunity, the innate immune system, specifically phagocytes such as 
macrophages and DCs, are also critical for regulating tumour growth. In addition to 
antigen presentation and cytokine production, Chao et al., recently showed that 
macrophages can also regulate cancer cell survival by programmed cell removal or 
phagocytosis[170].  Programmed cell removal is a key mechanism that links programmed 
cell death to the removal of the dying cell[170]. Under physiologic conditions, 
programmed cell removal of damaged and dying cells by macrophages is thought to be 
crucial for maintaining immune homeostasis[171].  Uncleared apoptotic and necrotic 
cells can incite inflammation through the release of toxic intracellular contents that can 
passively leak from cell corpses [172]. Regardless of whether phagocytes are engulfing 
dying cells or tumour cells, it is imperative that they be able to discern between their 
targets and healthy cells and also know where to find them. Phagocytic engulfment 
depends on the relative expression of pro-phagocytic and anti-phagocytic signals on the 
target cell as well as localization signals. Theses cues are referred to as “eat-me”, “don’t- 
eat-me” and “come-get-me” or “find-me” signals[173]. 
 
1.12.1 “Eat-Me Signals”  
 
“Eat-me” signals serve as markers for phagocytes to identify and engulf dying or 
damaged cells. These signals are often newly upregulated or modified existing molecules 
that can either appear on or change the charge of the cell surface[164, 174-176]. 
Professional phagocytes and semi-professional phagocytes employ cell-surface receptors 
to directly and indirectly bind to these “eat-me” signals to induce phagocytosis. There are 
numerous classes of phagocytic receptors including scavenger receptors (ex. CD36), 
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integrins (αvβ3 integrin receptor), lectins, and tyrosine kinases (ex. MerTK) to name a 
few[177-179].  
 
The most common and best-characterized “eat-me” signal is the membrane phospholipid, 
phosphatidylserine (PS). PS exposure occurs very early during the apoptotic process and 
is almost universal in its requirement for engulfment[112, 180-183]. PS is a phospholipid 
that is bound to the inner leaflet of the cellular membrane in healthy cells. Upon initiation 
of the cell death program, inhibition of a scramblase that normally confines PS to the 
inner leaflet, allows for the translocation of PS to the outer plasma membrane. In all cells 
capable of engulfment a PS receptor is universally expressed.  
 
After engagement of PS, the resulting phagocytic process can result in changes in the 
cellular microenvironment. For example PS mediated engulfment promotes the release of 
TGF-β while inhibiting TNF-α production, promoting an anti-inflammatory response by 
the phagocyte[167]. PS can bind to receptors directly in the case of KIM-1 or via 
bridging molecules such as milk-fat-globule-EGF factor 8 (MFG-E8), serum protein S 
growth arrest-specific 6 (GAS 6) and B2 glycoprotein 1 (B2GP1)[184]. PS bound to 
MFG-E8 on apoptotic cells can be recognized by αvβ3 integrins on macrophages and 
dendritic cells[185, 186]. Knockout studies of a phosphatidylserine receptor by M. Li et 
al., demonstrated the necessity of PS in the phagocytosis of apoptotic cells[187]. PS 
exposure however, is not sufficient. Studies have shown that in healthy erythrocytes 
coated with PS, PS expression alone was not sufficient to induce adhesion or 
internalization of live red blood cells[188].  
 
1.12.2 “Don’t-Eat-Me Signals”  
 
During the surveillance process, phagocytes will encounter live cells that do not need to 
be destroyed. Therefore there must be a mechanism that allows immune and non-immune 
cells to differentiate between healthy and apoptotic cells. Studies by Brown et al., 
highlighted that the interaction between CD31 molecules on live leukocytes and 
macrophages facilitated the detachment of leukocytes from the macrophages[189]. 
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Additionally, Brown also demonstrated that during apoptosis this detachment process 
between leukocytes and macrophages was inhibited. Thus CD31 functioned as a “don’t-
eat-me” signal.  
 
The idea of “don’t-eat-me” signals or other repulsive signals coincides with the theory 
that ‘markers of self’ must also exist to allow the immune system to discern between 
foreign and potentially dangerous, and self and potentially harmless. For example CD47 
expressed on red blood cells sends negative engulfment signals via signal regulatory 
protein α (SIRPα) to splenic macrophages to not eat them[190]. CD47 is expressed on 
numerous cell types and binds to SIRPα on macrophages to prevent the accumulation of 
myosin-11A at the phagocytic synapse [191]. In the context of cancers, recent efforts 
have been directed towards exploiting the expression of “don’t-eat-me” signals on 
various cancer forms. Wessman and colleagues have revealed that tumours can evade 
phagocytosis of macrophages by expressing “don’t-eat-me” signals such as CD47[170]. 
CD47 expression has been characterized on seven major types of cancer and is therefore 
being examined as a means to manipulate tumour survival[192]. The SIRPα receptor is 
expressed on macrophages, T-cells and dendritic cells to negatively regulate phagocytosis 
[190, 191, 193-195]. Therefore tumours can evade phagocytosis and immune detection 
by all of the above-mentioned pathways, ensuring their survival. Figure 1.2 represents 
the influence of “don’t-eat-me signals” on immune cells. 
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Figure 1.2 The result of CD47 expression on tumour cell survival. The expression of 
CD47 by tumour cells may serve as a way to evade immune detection by numerous 
immune cells including T-cell, macrophages and dendritic cells. The characterization of 
CD47 on seven major cancer forms has prompted research into the neutralization of 
CD47 as a means for tumour detection. 
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Adapted from Chao et al., 2012[170] 
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1.12.3 “Come-and-Get-Me Signals” 
 
“Don’t-eat-me” and “eat-me” signals serve as critical mediators of phagocytosis. 
However these signals are deemed sufficient for efferocytosis only when phagocytes are 
in close proximity with their apoptotic targets. When the phagocyte is not within the 
immediate environment, it has no way of knowing if apoptotic cells are in need of 
clearance before they become necrotic. As a result, attraction signals must exist that 
induce the rapid migration of phagocytes to the site of interest in order to prevent 
necrosis[196] and autoimmunity. Lauber et al., demonstrated using an in vitro transwell 
migration assay, that the supernatants of apoptotic cells contained various 
chemoattractants for monocytes and primary macrophages[197]. The authors show that 
apoptotic cells, and not non-apoptotic cells, released chemotactic factors via caspase-3 
mediated Ca2+ release that would draw phagocytes to them. Documented “come-and-get-
me” signals include lysophosphatidylcholine (LPC), S19 ribosomal dimers, endothelial 
monocyte-activating peptide and CX3CL1 [111, 172, 198]. Studies have shown that 
dying cells can actively release “come-and-get-me ” signals recruiting macrophages and 
monocytes to remove apoptotic cells[173, 199]. Similar findings were demonstrated in 
MCF7 breast cancer cells, where post induction of apoptosis, apoptotic breast cancer cells 
would release LPC, attracting human acute monocytic leukemia (THP-1) monocytes in 
vitro[197].  As a result of “come-and-get-me” or “find-me” signalling, phagocytes can 
effectively recruit semi-professional and professional macrophages that will engulf “eat-
me” signal expressing apoptotic cargo.  
 
1.13.0 Kidney Injury Molecule-1  
 
Kidney Injury Molecule-1 (KIM-1) was first discovered as the hepatitis A virus cellular 
receptor 1 (HAVCR1) [200]. It was then observed in the kidney epithelium where the 
structural similarities became known [201] and then again in T-cells[202]. As part of its 
characterization in T-cells, KIM-1 is also referred to as T-cell immunoglobulin mucin-1 
(TIM-1) and is thought to function as a co-stimulatory molecule in T-cell activation[203]. 
Human TIM-1/KIM-1, TIM-3 and TIM-4 belong to the T-cell immunoglobulin mucin 
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(TIM) gene family that have been characterized as influencing factors on a variety of cell 
types including T-cells [204-207], dendritic cells[208-210], B-cells [211], NK cells[212, 
213] and monocytes/macrophages[214-218]. Each of the TIM-1 gene family members is 
a type 1 transmembrane glycoprotein. The structure of KIM-1 is characterized by an 
extracellular immunoglobulin (Ig) like domain, followed by mucin domain containing O-
glycosylation and N-glycosylation sites and finally a short intracellular and 
transmembrane domain. A cartoon diagram depicting the structure of human KIM-1 is in 
Appendix 1.1. The molecular weight of KIM-1 is approximately 100kDa and can 
undergo spontaneous extracellular cleavage resulting in a 90kDa soluble fragment and a 
15 kDa transmembrane component, with the ectodomain portion released into the lumen 
of the tubule[219, 220].  
 
In 2008 Ichimura et al., demonstrated the ability of KIM-1 to bind to the ‘eat-me’ signal 
phosphatidylserine (PS) on the surface of apoptotic and necrotic cells, resulting in their 
engulfment[117]. The same is true of TIM-1 and TIM-4, with the strongest mediator 
being TIM-1[117]. Structural interactions are mediated by the hydrophobic head of PS 
inserting itself into the metal ion binding side in the Ig domain of KIM-1. KIM-1 can 
bind to other proteins such as oxidized LDL, necrotic debris, phosphatidylethanolamine 
(PE) and phosphatidylcholine (PC). Therefore, KIM-1 is also regarded as a scavenger 
receptor but its highest affinity is to PS[219, 221, 222]. The cytoplasmic domain has 
various cell signalling capacities through the MAP kinase stress pathway and JAK/STAT 
signalling families[223, 224].  
 
In relation to the kidney, KIM-1 was identified as part of an mRNA screen for genes 
upregulated on proximal tubule epithelial cells 24 to 48 hours after kidney injury in rats 
subjected to ischemia reperfusion injury (IRI)[225], a form of injury that mimics acute 
kidney injury (AKI) in humans and IRI during transplantation of solid organs[201]. KIM-
1 is unique in that it is the only characterized molecule on epithelial cells that transforms 
cells into semi-professional phagocytes[226]. KIM-1 expressing cells are characterized 
by an increase in 5-bromodeoxyuridine (BrdU), which is a marker for proliferation and 
vimetin, a marker for dedifferentiation[227]. In fact multiple studies exist linking the 
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dedifferentiation of kidney epithelial cells to KIM-1 expression[228-230]  
 
Beyond conferring the ability to induce proximal tubular epithelial cells to become semi-
professional phagocytes, KIM-1 is being tested as a strong biomarker for kidney 
damage[227, 230, 231]. The absence of KIM-1 expression in the normal kidney, its rapid 
and significant expression in the proximal tubule post-injury, its persistence until full 
recovery and the fact that robust and stable ectodomain cleavage is correlated to damage 
degree, make KIM-1 a potentially strong biomarker[225]. A recent study by Tonomura et 
al., tested thirteen highly used biomarkers for injury and concluded that KIM-1 was not 
only the most sensitive but the most accurate predictor of damage, even outperforming 
serum creatinine[232-234]. These data suggest that KIM-1 is upregulated in kidney in an 
injury-specific fashion to mediate clearance of apoptotic cells by tubular epithelial cells. 
 
1.14.0 Renal Cell Carcinoma  
 
The prevalence of kidney cancers throughout the world presents the need for rapid and 
effective curative and preventative solutions. Kidney cancer is among the ten most 
frequent cancers in the Western world[235] with renal cell carcinoma (RCC) representing 
90% of those cases[236]. Despite advances in imaging techniques and diagnoses tools, 
20-30% of diagnosed cases exhibit metastases[237] and 95% of those are fatal due to late 
stage identification[238]. Additionally, beyond nephrectomy or chemotherapy, prognosis 
for RCC patients is extremely poor. The only FDA approved treatment for RCC is an IL-
2 based treatment, approved over twenty years ago[239]. The complexities with 
developing novel treatments lies within the inherent toxic nature of the molecules used. 
For example various groups have highlighted that with the current regimens used for IL-2 
treatment, even in small molecule minimally toxic therapies, the systemic effects can be 
taxing, rendering IL-2 somewhat ineffective[240]. In RCC clinical therapies, 15-20% of 
patients on average withdraw from treatment and 30-40% required a reduced dose of the 
drug[241-246]. Standard treatment for RCC is complete resection by either a radical or 
partial nephrectomy and remains the mainstay of curative treatment[247]. Thus, treatment 
is usually limited to surgical nephrectomy, which is a significant risk factor for the 
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development of chronic kidney disease[248]. Furthermore the resistive nature of RCC to 
chemotherapy necessitates alternative forms of therapies that can increase patient 
survival[249].  
 
1.15.0 KIM-1 is expressed by many human cancers 
 
Beyond the kidney, others have demonstrated the expression of KIM-1 protein in 
approximately 40% of ccRCCs [250].  In a screen done for human KIM-1 mRNA levels 
in various cancers, Lin and colleagues found detectable levels of KIM-1 mRNA in non-
clear cell lung carcinomas (NSCLC) and ovarian and renal carcinomas[251]. The 
significance of KIM-1 expression in cancers however, remains unclear. A study done in 
2004 using the 769P renal cell carcinoma (RCC) cell line demonstrated the role of KIM-1 
in blocking the expression of differentiation markers in epithelial cells and contributing to 
the metastasis of tumours[252]. A second epidemiological study looked at 
trichloroethylene (TCE) and renal cancer. In this study patients exposed to critical levels 
of TCE ultimately developed renal cancer and all had elevated levels of KIM-1[253]. In 
contrast a study using geraniol (GOH), a chemoprotective agent, showed that GOH 
treatment reduced the levels of KIM-1 expression in rat renal tumours [254]. The area of 
KIM-1 expression as a direct influencing factor as opposed to predictive factor of tumour 
development is highly understudied. Furthermore the signalling pathways of KIM-1 in 
cancers have yet to be examined.  
 
The role of shed KIM-1 as a predictive biomarker for RCC and other kidney injuries has 
been highly characterized[231]. A retrospective study done by Cuadros and colleagues in 
2013 correlated higher urinary (uKIM-1) and cytosolic levels of KIM-1 to a more 
aggressive and invasive phenotype in RCC patients[250]. Another group examining 
urinary neutrophil geletinase-associated lipocalin (uNGAL) and uKIM-1 found uKIM-1 
in conjunction with uNGAL was predictive in 91.6% of RCC patients of disease 
status[255]. A third group examining urine KIM-1 levels post-nephrectomy in a KIM-1 
positive population found uKIM-1 levels fell in accordance with the removal of renal 
masses, indicating a relationship between mass presence and KIM-1 level[238]. An 
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additional study showed a linear correlation between uKIM-1 and tumour size pre-
nephrectomy for RCC[256]. A follow-up study done in 2014 demonstrated that the 
shedding of KIM-1 activates the IL-16/STAT-3/HIF-1α pathway that is connected to 
angiogenesis and tumour growth pathways[257]. The large amount of evidence 
highlighting the potential role of KIM-1 in influencing RCC tumour outcome warrants 
further investigation into potential mechanisms by which KIM-1 expression may confer 
an advantage to RCC tumours.  
 
1.16.0 Foundational Work and Thesis Rationale 
 
1.16.1 Foundational Work 
 
Preliminary work done by Dr. Gunaratnam, suggested that KIM-1 expressing kidney 
tubular epithelial cells might regulate extracellular DAMPs (HMGB1) through 
efferocytosis, as seen in Figure 1.3. Here, he added apoptotic cells (at an effector to 
target ratio of 1:2) to cultures of renal epithelial cells expressing (WT-PK1) and not 
expressing KIM-1 (pcDNA-PK1). After a 24 hour incubation period, the resultant 
conditioned cell media and lysates were analyzed by Western blot for the presence of 
HMGB1. Compared to that of control cells not expressing KIM-1, he observed 
significantly more intracellular HMGB1 in the lysates and less HMGB1 in the 
conditioned medium of KIM-1-expressing cells when exposed to thymocytes. This 
clearly demonstrated a role for KIM-1 in limiting HMGB1 release. It is based on this 
work that our lab decided to look at how KIM-1 might regulate HMGB1 release from 
dying cells.  
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Figure 1.3 KIM-1 expression prevents the leakage of HMGB1 from apoptotic cells. Pig 
tubular cells were transfected with pcDNA-KIM-1 or pcDNA alone and fed apoptotic 
thymocytes (Tx). The leakage of HMGB1 was measured in the media and a difference in 
HMGB1 release as a by-product of KIM-1 expression was observed.  
 
Adapted from Gunaratnam, unpublished 
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1.16.2 Thesis Rationale  
 
RCC accounts for approximately 3% of all new cancer cases and the incidence rates for 
all stages have been rising steadily over the last three decades [258]. It is the most 
common and deadly form of urogenital cancer in humans[258]. Unfortunately, RCC is 
relatively resistant to chemotherapy and radiotherapy making surgery the mainstay of 
therapy for patients. KIM-1 is a cell-surface receptor for PS that is widely expressed in 
RCC tumours[231, 251, 259]. KIM-1 overexpression in a variety of cells including 
epithelial cells converts them into avid phagocytes for apoptotic[117, 221] and 
necrotic[117] cells. Work done by Lin and Vila demonstrated HAVCR-1/KIM-1 mRNA 
and protein expression in numerous other types of cancers[251, 252]. Moreover, RCC 
cell lines established from patient tumours constitutively express KIM-1[117, 221]). The 
above data together with the possibility that KIM-1 expression and shedding by RCC 
tumours may be a predictive biomarker of tumour progression[259] led us to explore 
further the role of KIM-1 in RCC tumours. The biological relevance of KIM-1 expression 
to the pathogenesis of cancer is unknown.  Phagocytes that ingest apoptotic cells actively 
suppress local inflammation while preventing the release of immunogenic contents (e.g. 
HMGB1) as they undergo secondary necrosis. When released into the extracellular 
milieu, intracellular proteins such as HMGB1 can serve as DAMPs to trigger the innate 
immune response. By contrast, cancer cell death elicited by certain chemotherapeutic 
agents such as anthracyclines is immunogenic [123]. Immunogenic death involves 
exposure of “eat-me” signals on the cell surface, as well as the release of soluble 
immunogenic signals or alarmins such as HMGB1 that serve to license DCs and 
macrophages to activate anti-tumour immunity [123]. The preliminary work done by Dr. 
Gunaratnam in Figure 1.3 suggested that KIM-1-expressing epithelial cells could limit 
the passive release of HMGB1 from apoptotic cells undergoing secondary necrosis and 
necrotic cells by rapidly clearing them from the extracellular milieu. Thus, we argued that 
the ability of RCC cells to alter the immunogenic tumour microenvironment (free 
HMGB1) resulting from cancer cell death (e.g. due to chemotherapy) might serve as a 
novel tumour evasion mechanism. Therefore, we hypothesized that the constitutive 
expression of KIM-1 by RCC cells would enable cancer cells to prevent the 
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activation of the innate immune system (DCs) by the passive release of alarmins 
(HMGB1) from uncleared apoptotic and necrotic cells in their tumour 
microenvironment.  A working model is seen in Figure 1.4. 
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Figure 1.4 Proposed model for KIM-1 mediated sequestration of DAMPs. (A) In the 
absence of danger signals, the release of HMGB1 from primary and secondary necrotic 
cells would result in immune activation. (B) The expression of KIM-1 would result in the 
phagocytosis of surrounding dying tumour cells and limit the release of HMGB1 and 
downstream activation 
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 (A) 
 
 
(B) 
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Chapter 2: Materials and Methods  
 
2.1.0 Cell Culture  
 
The origins of the cell lines used in this thesis are outlined in Table 2.1. All cells were 
cultured at 37ºC and 5% CO2. Cells were grown in Roswell Park Memorial Institute 
(RPMI) media, Dulbecco’s Modified Eagle’s Medium (DMEM) or Eagle’s Minimum 
Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS). FBS 
components were purchased from Lonza (Basel, Switzerland). Penicillin Streptomycin 
(P/S) was purchased from Wisent Inc. Geneticin (G418) was purchased from Santa Cruz 
Biotechnology (Dallas, TX). Cells that were not donated were purchased from ATCC. 
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Table 2.1 List of cell lines 
Cell Line Host Type Growth 
Conditions 
Source 
A549 Human Lung carcinoma RPM1 +10% FBS Dr. John 
DiGuglielmo 
OCC-1 Human Ovarian 
carcinoma 
RPMI + 10% FBS 
+ 1% P/S 
Dr. DiMattia 
769P Human Renal carcinoma RPMI + 10% FBS 
+ 1% P/S 
ATCC 
786-0 Human Renal 
adenocarcinoma 
RPMI + 10% FBS 
+ 1% P/S 
ATCC 
SKOV3 Human Ovarian 
adenocarcinoma 
RPMI + 10% FBS 
+ 1% P/S 
Dr. Gabriel 
DiMattia 
PC3 Human Prostate 
adenocarcinoma 
RPMI + 10% FBS 
+ 1% P/S 
Dr. Paula Foster 
ACHN Human Renal cell 
adenocarcinoma 
EMEM + 10% FBS 
+1% P/S 
Dr. Alp Sener 
HeLa Human Cervical 
epithelial 
adenocarcinoma 
 
EMEM + 10% FBS ATCC 
LLC-KIM-1-PK1 Pig Kidney epithelial DMEM + 10% 
FBS + G418 
(400ug/ml) 
Self established 
LLC-PK1 Pig Kidney epithelial DMEM + 10% 
FBS + G418 
(400ug/ml) 
ATCC 
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2.2.0 Plasmid Transfection  
 
LLC-PK1 cells are pig kidney epithelial cells that were used to establish the LLC-KIM-1-
PK1 (WT-PK1) cell line. One million LLC-PK1 cells were plated 24 hours prior to 
transfection on a 10cm2 dish (BD Biosciences Franklin Lakes, NJ). When cells reached 
70-85% confluence they were transfected using Lipofectamine 2000 (Life Technologies, 
Carlsbad, CA) with either an empty pcDNA3 plasmid or pcDNA3 encoding full length 
KIM-1 cDNA. G418-resistant (Santa Cruz Biotechnology Inc.) stable cell lines were 
selected from positive colonies grown in complete medium containing 400 ng/µl of G418 
as described elsewhere [117, 201, 260].  
 
2.3.0 Thymocyte Culture and Induction of Apoptosis or Necrosis  
 
Single-cell suspensions of primary thymocytes were taken from the thymi of C57BL/6 
mice ranging from 6-8 weeks of age by grinding them over cell strainers (BD 
Biosciences) using a 10µl syringe plunger (BD Biosciences). To remove red blood cells, 
the thymocyte suspension was resuspended in ACK lysis buffer (Lonza) for 5 minutes. 
Thymocytes were washed three times in ice-cold PBS and resuspended in RPMI media 
containing 10% FBS and 1% P/S and incubated at 37ºC and 5% CO2 to keep them alive.  
 
For induction of apoptosis, cells were counted and placed under ultraviolet (UV) 
radiation (254nm) for 3 minutes. For phagocytosis assays, cells were first labeled with 
carboxyfluorescein succinimidyl ester (CFSE),  (Invitrogen, Carlsbad, CA) at a dilution 
of 1µl/ml for 5 minutes, washed with complete medium to remove any excess CFSE and 
then left for a minimum of 8 hours prior to use at 37ºC and 5% CO2. 
 
For inducing necrosis, cells were counted using a hemocytometer (VWR, Radnor, PA) 
and placed in a water bath at 56ºC for 15 minutes in 1.5 ml eppendorf microcentrifuge 
tubes (Eppendorf, Hamburg, Germany). Cells were used immediately after heat shock.  
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2.4.0 RNA Extraction 
 
For total RNA isolation from cells cultured in 6-well tissue culture plates, 1ml of Trizol 
(Life Technologies) was added per well and left to incubate for 2-3 minutes at room 
temperature. Total RNA was isolated according to the protocol established by 
Chomczynski & Sacchi, in 1987[261]. Samples were then resuspended in 30 µl of 
diethylpyrocarbonate (DEPC) treated water. The concentration and purity of each RNA 
sample was determined by measuring the absorbance at 260nm as well as the 260/280 
and 260/230 nm ratios using a Nanodrop 1000 spectrophotometer (Nanodrop Products, 
Wilmington, DE). Samples were then stored at -80ºC until used for cDNA synthesis. 
2.5.0 Complementary DNA (cDNA) synthesis 
 
As part of first strand synthesis, 1µg of total RNA was combined with a 40nM Oligo-dT 
primer (New England Biolabs, Ipswich, MA), 10nM dNTP mix (Quantas, Gaithersburg, 
MD) and DEPC water in a total reaction volume of 10 µL. The samples were heated for 5 
minutes at 80ºC using a Mastercycler thermocycler (Eppendorf, Hamburg, Germany). 
Next 10xRT buffer, M-MuLV Reverse Transcriptase and RNAse Inhibitor at 10U/µl 
(New England Biolabs, Ipswich, MA) were added to a final volume of 20µl. Cycling 
parameters were as follows: 42ºC for 60 minutes, 90ºC for 10 minutes and 4ºC until 
ready for use. Samples were stored at -20ºC.  
2.6.0 Quantitative Real Time PCR (qRT-PCR) 
 
For qRT-PCR, 100ng of the cDNA stock was amplified using the Perfecta SYBR Green 
Fastmix with ROX (Quantas, Gaithersburg, MD). Primers were purchased from 
Integrated DNA Technologies (IDT, Coralville, IA) and designed by myself, previous lab 
members or taken from former labs.  Primers were added at 250nM concentrations and 
are listed in Table 2.2. Amplification was done using the StepOne Plus thermocycler 
(Life Technologies) and analyzed with the corresponding software. The parameters for 
the run included one cycle of 95ºC for 30 seconds, followed by 40 cycles at a temperature 
between 0-5ºC lower then the primer melting temperatures (Tm) and finally a melt curve 
dissociation step. Relative gene expression was calculated using the 2-ΔΔCT method and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for normalization[262].  
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Table 2.2 Human PCR primers  
Gene Target Forward Primer (5’à3’) Reverse Primer (5”à  3’) Product Size 
KIM-1 GAA GTG GCT ACT GGT 
TCA TGG 
ACG ACT GTT CGA ACG 
AGC AC 
260 
GAPDH CTC TTC TGC TCC TCC TGT 
TCG AC 
TGA GCA ATG TGG CTC 
GGC T 
162 
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2.7.0 KIM-1 siRNA Knockdown 
 
Transfection of KIM-1 siRNA was performed in Opti-MEM Media (Life Technologies) 
in conjunction with Lipofectamine 2000 (Life Technologies) using the Life Technologies 
protocol. 24 hours prior to transfection, cells were plated at between 60-75% confluence 
in 2 mls per well of RPMI media containing 10% FBS and 1% P/S. Two hours prior to 
transfection, the medium was exchanged with 1 ml of Opti-MEM media in each well of 
the 6-well dish. Commercially available KIM-1 siRNA (sc-61691) or control siRNA (sc-
37007) were purchased from Santa Cruz Biotechnology and transfected at a final 
concentration of 10nM into cells plated in 6-well plates containing 500ul of Opti-MEM 
media per well. Cells were given an additional 1.5 µl of RPM1 containing 10% FBS 
media to ensure adequate survival for 24 hours until apoptotic or necrotic cells were 
added.  
2.8.0 Western Blot Procedure 
 
After the appropriate treatment, cells were harvested at approximately 90-95% 
confluence and lysed using a lysis buffer containing 4% sodium dodecyl sulfate (SDS) in 
PBS[7]. Lysate samples were then scraped using cell scrapers (Mandel, Guelph, ON) and 
sheared with a 26-gauge syringe (BD Sciences). Samples were then boiled for 5 minutes 
at 98ºC and quantified using the Pierce BCA Protein Assay Kit (Thermo Scientific, 
Waltham, MA). Typically, 60µg of total protein was loaded in each well for SDS-PAGE. 
For conditioned media samples used for detection of soluble HMGB1, samples were 
centrifuged at 7.6 x relative centrifugal force (RCF) for 5 minutes to remove any cellular 
material. Approximately 80% of the sample was collected to ensure cellular debris was 
left behind. All lysate and media samples were diluted in water to total volume of 55µl 
containing 9µl of 6x gel loading dye (New England Biolabs).  A total volume of 50µl was 
loaded in each well of a 10-well 10% SDS page gel using the Bio-Rad Mini Trans-Blot 
system (BioRad, Mississauga, ON). The samples were then transferred onto a PVDF 
membrane (EMD Millipore, Darmstadt, Germany) and blocked with 5% skim milk 
powder (Carnation Inc., Switzerland) in PBS and .2% Tween-20 for 30 minutes to one 
hour. The appropriate primary antibody was then applied at the concentration listed 
below and incubated overnight at 4oC on a rocker (VWR Canada). A secondary antibody 
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conjugated to horse radish peroxidase (HRP) was applied at varying dilutions for an hour 
to two hours and then developed using HRP-specific Luminata Forte (EMD Millipore) 
and imaged with the Licor Imaging system (Mandel Scientific). The images were 
digitally visualized and quantified by densitometry using the ImageJ Software. A list of 
all the primary and secondary antibodies used in our studies is listed below in Table 2.3 
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Table 2.3 Primary and secondary antibodies for western blot  
Specificity Description 
and predicted 
MW of band 
Usage Dilution 
Factor from 
Stock 
Source 
KIM-1 Intracellular 
KIM-1 binding 
Size: 100kDa 
Primary 1: 1500 Ichimura Lab 
(Harvard, MA) 
HMGB1 Chromosomal 
protein 
Size: 29kDa 
Primary 1:1000 Sigma-Aldrich 
AKG-3 Extracellular 
KIM-1 
Size: 95kDa 
Primary 1:3 Bonventre Lab 
(Harvard, MA) 
Actin Beta-actin 
loading control 
Size: 40kDa 
Primary 1:1500 Novus 
Biologicals 
Goat IgG Goat specific 
HRP conjugate 
Secondary 1:20,000 Jackson 
Research Labs 
Mouse IgG Goat specific 
HRP conjugate 
Secondary 1:30,000 Jackson 
Research Labs 
Rabbit IgG Goat specific 
HRP conjugate 
Secondary 1:30,000 Jackson 
Research Labs 
Note: All primary and secondary antibodies are diluted in 5% skim milk powder in 0.2% 
PBS tween and added to the membrane  
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2.9.0 Dendritic Cell Culture 
 
Primary bone marrow-derived dendritic cells were isolated from the bone marrow of 6-8 
week-old C57BL/6 mice and cultured in IL-4 and GM-CSF (Santa Cruz) for a span of 
one week. The bone marrow was first isolated from mice and washed multiple times with 
a syringe and PBS. Cells were then spun down at 500 x g and resuspended in RPMI and 
10% FBS with non-essential amino acids (NEAA), and sodium pyruvate. IL-4 and GM-
CSF was added in a 1µl/ml concentration and the media was changed every 2 days with 
new IL-4 and GM-CSF added. Cells were then plated the night prior to usage. 
2.8.0 Dendritic Cell Marker Staining 	  
After the associated experiments were complete, DCs were washed with PBS and 
transferred into fluorescence assisted cell sorting (FACS) tubes (BD Sciences). The 
samples were spun down at 350 x g for 5 minutes using a centrifuge (Eppendorf) and 
then incubated with a mixture of the following markers; an isotype control, CD11c, 
CD40, CD86 (Santa Cruz) and unstained solutions all resuspended in FACS buffer. 2 mls 
of PBS was then added to each tube, spun down, and resuspended in 1% 
paraformaldehyde (PFA) FACS buffer (Gunaratnam Lab).  
2.10.0 KIM-1 Surface Staining 
 
Cells were harvested in a single cell suspension containing cell staining buffer 
(Biolegend). Cells were then centrifuged at 350 x g for five minutes followed by 
resuspension in staining buffer containing PE-anti-KIM-1 antibody (Biolegend) at 1 
µg/ml and incubated for 15-20 minutes on ice in the dark. Cells were then washed twice 
with staining buffer and spun at 350 x g for 5 minutes prior to analysis on the LSR II 
flow cytometer at the Robarts Research Institute.  
2.11.0 Annexin V/PI staining and Analysis 
 
Determination of live, apoptotic and necrotic status for thymocytes was done using 
Annexin V and Propidium Iodide (PI) (Biolegend) staining. Protocol used was optimized 
by Dr. Xizhong Zhang in our laboratory. Briefly, single-cell suspensions of live or killed 
thymocytes were incubated with 40uM of Annexin-V-FITC for 30 minutes after which 
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10mM PI was added. After staining each group, samples were analyzed on a FACS 
Calibur cytometer (BD Sciences) equipped with 488 and 633 nm lasers, and emission 
filters for FITC, PI, APC and AlexaFluor633 at Robarts Research Institute. Data was 
analyzed with FlowJo Mac software (Tree Star Inc.). Percentage of maximum intensity 
was calculated by dividing the MFI of each sample by that of the maximally affected 
sample, (i.e. percent max = MFIsample/ MFImax*100). 
 
For phagocytosis assays, apoptotic cells were labeled with CFSE at a concentration of 
1µl/1 million cells and a minimum of 8 hours. Thymocytes were added to target cells and 
left for 24 hours to allow for sufficient phagocytosis. Percent positive CFSE cells were 
run using FACS Calibur (BD Sciences). All analysis of flow data was done using FlowJo 
(Treestar, Ashland, OR). Forward-scatter/side-scatter (FSC/SSC) ratio was used to 
exclude apoptotic cell debris. 
A summary of all Flow Cytometry antibodies used during the course of this project can 
be found in Table 2.4 
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Table 2.4 Antibodies for flow cytometry 
Antibody  Species  Fluorochrome  Manufacturer  
CD11c Mouse APC Biolegend 
CD40 Mouse FITC Biolegend 
CD86 Mouse Brilliant Violet 421 Biolegend 
CFSE Mouse FITC Biolegend 
Annexin V Mouse FITC Biolegend 
Propidium Iodide  Mouse PI Biolegend 
KIM-1 Human  PE Biolegend 
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2.12.0 Animals 
 
Six to eight week-old male C57BL/6 mice were purchased from Charles River 
Laboratories and housed at the animal facility at Western University (London, ON, 
Canada). Experiments were conducted by following established guidelines for animal 
care approved by the University Council on Animal Care at Western University. 
 
2.13.0 Statistical Analyses 
 
All statistical analysis was calculated using GraphPad Prism 5.01 (La Jolla, CA). Error 
bars among samples reflect the standard error of the mean (SEM). Significant differences 
between samples were determined using an unpaired t-test with p<0.05 considered 
significant for all experiments. * is p<0.05, ** is p<0.01, and *** is p<0.001. For 
grouped analyses a two-way ANOVA test with a Bonferroni post-test correction was 
used. P<0.05 is considered significant for all experiments. * is p<0.05, ** is p<0.01, and 
*** is p<0.001 
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Chapter 3.0 Results  
 
3.1 Characterizing the expression of KIM-1 in human cancers 
 
In order to evaluate the role of KIM-1 as an immune evasion mechanism in cancer, we 
first characterized the expression levels of KIM-1 on a diverse group of cancer cell lines. 
Established cell lines from patients with prostate cancer, lung cancer, renal cancer, 
ovarian cancer and cervical cancer were grown in vitro. Total RNA was isolated from 
each of these cell types after culturing them in 6-well plates for 24 hours. Samples were 
then reverse transcribed and amplified using quantitative PCR (Figure 3.1). As shown 
below, KIM-1 mRNA was detected in all the tested cancer cell lines except for HeLa and 
OCC-1. KIM-1 gene expression was significantly higher in the renal cancer cells tested 
and is in keeping with what has been reported[263]. Nonetheless, KIM-1 mRNA was 
observed in the prostate and lung cancer cell lines as well. Because 769P and 786-0 cells 
expressed the highest levels of KIM-1, these were selected for further study. Next, the 
surface expression of KIM-1 protein was examined in both 769P and 786-0 cells by flow 
cytometry. For both 769P and 786-0 cells, LLC-PK1 cells that do not express human 
KIM-1 were used as a negative control. The lack of KIM-1 in LLC-PK1 cells was 
characterized previously[264]. Approximately 96% and 92% of the 769P cells and 786-0 
cells stained positive for KIM-1 respectively relative to the negative control (3.71%).  
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Figure 3.1 Comparison of KIM-1 expression in various cancer cell lines. HeLa 
(cervical), OCC-1 (ovarian), SKOV3 (ovarian), PC3 (prostate), A549 (lung), ACHN 
(renal), 786-0 (renal) and 769P (renal) cancer cells were grown in culture and once 
confluent processed with Trizol to make total RNA. RNA samples were then quantified, 
synthesized into cDNA and then amplified using qRT-PCR. GAPDH was used as a 
reference gene and ROX was used as a normalizer dye. Data represents three independent 
experiments. Y-axis represents fold change in gene expression relative to HeLa cells. 
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Figure 3.2 Surface staining for KIM-1 on 769P and 786-0 cells. Cells were grown until 
confluent, scraped from the well and stained with PE conjugated hKIM-1 antibody. Cells 
were resuspended in cell-staining buffer and incubated in the dark for 15 minutes at 
1µg/ml concentrations. Cells were then analyzed using LSR II and fixed with PFA. 769P 
and 786-0 cells were 96% and 92.9% positive for surface KIM-1 expression represented 
by the far right column. 10,000 events were collected. Surface staining in Figure 3.2 is 
representative of one of three experiments done to confirm KIM-1 surface expression. 
Error bars represent standard deviation. 
50	  
	  
LLC-PK1 cells (negative control) 
   FSC 
786-O renal cancer  
 
 
769P renal cancer 
 
 
	   	  	  
hKIM-­‐1	  
	  
Si
de
	  S
ca
tt
er
	  
a	  
51	  
	  
3.2 KIM-1 expression is required for phagocytosis 
 
Based on the expression profile of KIM-1 mRNA and protein, we chose the 769P cells as 
our model system to test our hypothesis within tumours. In order to determine the impact 
of KIM-1 mediated phagocytosis of apoptotic and necrotic cells in cancers we used an 
already established porcine kidney tubular epithelial cell line (LLC-PK1) that 
overexpresses human KIM-1[117, 265]. Our lab has previously confirmed that KIM-1 
expression in LLC-PK1 cells is sufficient to transform these cells into semi-professional 
phagocytes for apoptotic and necrotic cells[117](Gandhi et al., submitted). As a result the 
LLC-PK1 model served as a positive control for the role of KIM-1 in our cancer model.  
LLC-PK1 pig tubular cells stably transfected with a pcDNA3 plasmid with (WT-KIM-1) 
or without KIM-1 (pcDNA-PK1) were characterized for their capacity to engulf apoptotic 
or necrotic thymocytes. First, primary mouse thymocytes were kept alive or killed by 
inducing apoptosis or necrosis and stained with Annexin V-FITC and PI to confirm cell 
death by necrotic or apoptotic pathways (Figure 3.3). Annexin V binds to PS on the outer 
membrane of cells once they become apoptotic. PI binds to exposed DNA fragments as a 
result of a loss of membrane integrity seen with necrosis. Live cells were established by 
keeping thymocytes in serum-supplemented media in an incubator for the course of the 
experiment. Apoptotic cells were produced by 3 minutes of UV-exposure followed by 
incubation for minimum 8 hours[266]. Lastly necrotic cells were generated by heat-shock 
in a water bath for 15 minutes at 56°C[267]. Live cells stained negative for both Annexin 
V and PI, whereas approximately 40% of apoptotic cells were positive for Annexin V 
with approximately 37 % double positive for both Annexin V and PI. While the Annexin 
V single-positive thymocytes were considered early apoptotic, the double-positive 
population was likely late apoptotic[268]. Lastly, the necrotic thymocytes were 
approximately 61% PI positive indicative of loss of membrane integrity typical of 
necrotic cells.  
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Figure 3.3 Characterization of live, apoptotic and necrotic thymocytes. Thymocytes 
were isolated from the thymic lobes of C57BL/6 mice and were cultured as outlined in 
the materials and methods section. Cells were then kept alive, made apoptotic through 
UV exposure or turned necrotic through heat shock. Cell status was confirmed through 
Annexin V and PI staining. Live cells stained Annexin V and PI negative. Apoptotic cells 
were Annexin V positive and late apoptotic cells were both Annexin V and PI positive, 
and necrotic cells were predominantly PI positive. Data is representative of one 
independent experiment and was analyzed via flow cytometry. Results have been verified 
more than three independent times. 
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Although the phagocytic capacity of KIM-1-PK1 and pcDNA-PK1 cells had been 
previously established [117], the long-term kinetics of apoptotic and necrotic cell-uptake 
had not been addressed. The presence and absence of cell-surface human KIM-1 
expression in WT-PK1 and pcDNA-PK1 cells is seen below (Figure 3.4). 44% of WT-
PK1 cells stained positive for surface KIM-1 expression whereas 3.71% of the pcDNA-
KIM-1 cells stained positive. Next, phagocytosis was quantified using flow cytometry 
after feeding either pcDNA-PK1 or WT-PK1 cells fluorescently-labeled thymocytes that 
had been rendered apoptotic or necrotic as described above. The percent of pcDNA-PK1 
(Figure 3.5A) and WT-PK1 cells (Figure 3.5B) engulfing either apoptotic or necrotic 
thymocytes is shown below. A representative gating strategy of one replicate can be seen 
in Appendix II. Lastly at the 24-hour time point, we did a comparison between the 
phagocytosis of live, apoptotic and necrotic cells by pcDNA vs. WT-PK1 cells. From this 
we decided to focus specifically on apoptotic and necrotic cells, as the phagocytosis of 
live cells was only minimal and yielded no difference between the two groups (Figure 
3.6).  
 
One shortfall to our method of evaluating phagocytosis is that a shift in fluorescence does 
not necessarily indicate internalization but instead may represent binding to the outside of 
the cell. Therefore, an alternative cell tracer, PHrodo dye (Invitrogen), was used instead 
of CFSE to label the apoptotic and necrotic cells before quantifying phagocytosis. 
PHrodo dye is a pH sensitive dye whose fluorescence intensity increases at an acidic pH. 
Apoptotic and necrotic cells labeled with PHrodo were expected to generate a more 
intense signal when delivered to the acidic environment of phagolysosomes indicating 
that the corpse was indeed inside the cell and not outside it. Phagocytosis experiments 
done using PHrodo verified our results.   
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Results shown in Figure 3.6 demonstrate that at 24-hours, WT-KIM-1 cells engulfed 
significantly more apoptotic and necrotic cells compared to pcDNA-PK1 cells. Moreover, 
WT-PK1 cells were on average 2-3 times more efficient at engulfing necrotic compared 
to apoptotic cells. Because the induction of necrosis often results in the disintegration of 
cells into debris that can confound the findings from our phagocytosis experiments, we 
compared the mean fluorescent intensity of the WT-PK1 cells that had engulfed either 
apoptotic or necrotic cells. The MFI findings (Appendix III) mirrored the percent 
phagocytosis data shown (Figure 3.6). Therefore WT-PK1 cells were more adept at 
internalizing necrotic cells than apoptotic cells. Importantly, the phagocytosis of live cells 
was significantly lower than that of apoptotic or necrotic cells at between 5- 7%. Also 
live cell-uptake was independent of KIM-1 expression suggesting that an alternative 
mechanism of their uptake by LLC-PK1 cells. 
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Figure 3.4. Surface staining for pig epithelial LLC-PK1 cells stably expressing human 
KIM-1. To confirm KIM-1 had been incorporated successfully into PK1 cells WT-PK1 
cells were surface stained for KIM-1 expression using a human PE conjugated anti-KIM-
1 antibody at 1µl/ml using the same method as in Figure 3.2.  Using flow cytometry ten 
thousand events were collected and gated on KIM-1 positive cells. The panel on the left 
represents control LLC-PK1 cells and on the left represents WT-KIM-1 cells. Surface 
staining represents one of three independent staining experiments. Analysis was 
completed using FlowJo Software.   
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Figure 3.5. KIM-1 expression enhances the phagocytosis of apoptotic and necrotic cells. 
pcDNA-PK1 (A) and WT-PK1 (B) cells were fed CFSE stained five million apoptotic 
and necrotic thymocytes respectively for 24 hours. Samples were then spun down, 
resuspended in FACS buffer and processed using a FACS Calibur. Ten thousand events 
were collected and gated against LLC-PK1 cells at WT-KIM-1 cells alone as a negative 
control respectively. The percent change in fluorescent intensity compared to the negative 
controls was used to establish a change in percent phagocytosis at each time point.  
Antibody concentrations were used at 1 µl/ml and staining procedure is listed in the 
materials and methods. Data represents three independent experiments. *** P<0.001 
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Figure 3.5A   
Control PK1 
           
 
Figure 3.5B 
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Figure 3.6 Representative trend in the phagocytosis of live, apoptotic and necrotic cells 
by KIM-1 and non-KIM-1 LLC-PK1 expressing cells. Representative phagocytosis of live 
(A), apoptotic cells (B), and necrotic cells (C) by KIM-1 and non-KIM-1 expressing cells 
using flow cytometry at 24 hours. A-C represent one experiment. Panel D is a 
comparison of phagocytosis data from three independent experiments from panels A-C. 
*** P<0.001. 
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3.3 KIM-1 is required for RCC- phagocytosis of apoptotic and necrotic cells  
 
A central premise to our hypothesis is that RCC cells possess the ability to engulf 
apoptotic and necrotic cells. Therefore, the phagocytic capacity of 769P cells was 
measured using flow cytometry. 769P cells were fed CFSE-labeled apoptotic or necrotic 
thymocytes for different periods of time and the engulfment of apoptotic (Figure 3.7A) 
and necrotic cells (Figure 3.7B) was quantified over a period of 24 hours to characterize 
phagocytosis within the 24 hour time frame our experiments were to be performed. Once 
again, similar experiments performed by Ola Ismail (Gunaratnam Lab) using PHrodo dye 
to label the dead cells helped confirm that we were not merely measuring surface binding 
but rather phagocytosis in our experimental results (data not shown). Fluorescent 
thymocytes were fed to 769P cells at different time points and all cells were harvested at 
the same time before analyzing the results by flow cytometry. The percent uptake of 
apoptotic cells was increased gradually over the 24 hour period tested. At 24 hours, the 
percent uptake of apoptotic and necrotic cells was 37.5% and 45.5% respectively.  These 
data demonstrated that 769P phagocytosis occurred in as little as 30 minutes and did not 
plateau up even at 24 hours. 
 
Having established that 769P cells could phagocytose both apoptotic and necrotic cells, 
we determined if KIM-1 was necessary for phagocytosis. 769P cells were either left 
untreated, transiently transfected with siRNA targeting human KIM-1 or non-specific 
control siRNA, which does bind KIM-1, using Lipofectamine 2000. As shown, 24 hours 
after transfection, KIM-1 siRNA appreciably inhibited KIM-1 protein expression in 769P 
cells as determined by Western blot (Figure 3.8A). As a result of siRNA treatment, KIM-
1 protein expression was reduced approximately 60% and was significantly lower than 
control siRNA transfected cells (Figure 3.8B). We then characterized the change in cell-
surface expression KIM-1 in 769P cells after siRNA knockdown via flow cytometry 
(Figure 3.8C). There was a 55% decrease in surface expression of KIM-1 in 769P cells 
treated with KIM-1 siRNA. In a different series of experiments, the effect of siRNA-
knockdown of KIM-1 was compared at 24 hours, 48 hours and 72 hours of incubation 
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(data not shown) and the 24-hour time point was determined to be optimal for further 
studies.   
 
Next, the effect of KIM-1 silencing on phagocytosis of both apoptotic (Figure 3.9A)  and 
necrotic cells by 769P cells was determined (Figure 3.9B). As a result of KIM-1 down-
regulation, phagocytosis of both apoptotic and necrotic cells was reduced by 60% in 
comparison to untreated controls. There was also no significant difference between the 
control siRNA transfected and untreated groups.  
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Figure 3.7 769P cells engulf both apoptotic and necrotic cells. 769P cells were fed CFSE 
labeled apoptotic (A) or necrotic (B) thymocytes at various time intervals to profile the 
optimal time point for phagocytosis. Samples were then collected and analyzed. 
Identification of CFSE positive cells was based on the 769P cell alone gate (negative 
control). Results are based on ten thousand events collected and represent three 
independent experiments via flow cytometry. *** P<0.001. 
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Figure 3.7A 
Apoptotic cells  
            
 
Figure 3.7B 
Necrotic cells 
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Figure 3.8 Knockdown of KIM-1 in 769P cancer cells. 769P renal cancer cells were 
transiently transfected with a human KIM-1 siRNA using OPTI-MEM media and 
Lipofectamine 2000. Final concentrations of control and KIM-1 siRNA were 10nM and 
untreated cells contained only OPTI-MEM media. Transfection was performed at 24 
hours and is represented here in triplicate. Panel (A) is representative of three blots 
acquired in three independent experiments. Panel (B) is a quantification of these using 
densitometry where knockdown was determined as the percent reduction in density from 
769P untreated cells. (C) Represents the change in surface staining of 769P cells in 
shRNA KIM-1 stable cells by FACS. ** p<0.01, ***  P<0.001. 
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Figure 3.9 Change in phagocytosis of apoptotic and necrotic cells in KIM-1 siRNA 
treated cells.  769P cells were transfected with hKIM-1 siRNA or control siRNA for 24 
hours and then fed CFSE apoptotic or necrotic thymocytes. Change in phagocytosis as a 
result of KIM-1 expression was measured via flow cytometry and gated relative to 
untreated cell phagocytosis. Panels A and B graphs represent triplicate experiments *** 
representing P<0.001. (A) Apoptotic cell phagocytosis and (B) Necrotic cell 
phagocytosis. 
 
69	  
	  
Figure 3.9A 
 
                  
 
Figure 3.9B 
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3.4 HMGB1 is released from apoptotic and necrotic cells 
 
HMGB1 is a nuclear structural protein that serves as a DAMP when released into the 
extracellular milieu[144, 269]. While HMGB1 has been shown to be released passively 
from necrotic cells due to loss of membrane integrity, apoptotic cells are believed to 
sequester HMGB1 in the nucleus [122]. We therefore characterized the release of 
HMGB1 from live, apoptotic and necrotic thymocytes. Equal numbers of thymocytes 
were untreated (kept alive) or treated as described previously (Materials and Methods 
section 2.3.0) to induce apoptosis or necrosis. Cells were then harvested at various time 
points after induction of cell death and the respective conditioned medium was analyzed 
by Western Blot for HMGB1 expression (Figure 3.10A). The experiment was completed 
in triplicate and the media samples were analyzed for relative HMGB1 expression 
(Figure 3.10B).  
 
During the 72-hour time period, necrotic cells exhibited a persistent release of HMGB1 
into the conditioned medium. While live thymocytes began to slowly leak HMGB1 
between 24 and 48 hours, apoptotic cells began releasing HMGB1 as soon as 8 hours of 
induction of cell death. At 72 hours, both live and dead thymocytes exhibited large 
amounts of HMGB1 into the extracellular medium. The leakage of HMGB1 from live 
cells appeared surprising, but it is known that live thymocytes do undergo spontaneous 
cell death under these conditions[270]. At 24 hours nearly 50% of the cellular HMGB1 
content had been released into the surrounding environment. Necrotic thymocytes 
however, began to release HMGB1 immediately into the surrounding media, 
demonstrated by the 15% leakage of HMGB1 at the zero hour time point. HMGB1 
leakage continued to increase steadily up to 72 hours and by 24 hours, had released 
approximately 75% of its cellular HMGB1 into the surrounding environment. Samples 
are graphed relative to HMGB1 release by necrotic cells at 72 hours using densitometry.  
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Figure 3.10 Passive release of intracellular of HMGB1 from live, apoptotic and necrotic 
thymocytes into conditioned media. Cells were induced to undergo necrosis, apoptosis or 
remain alive and were plated in equal numbers into 6 well plates after CFSE labeling. At 
each time point, cells were collected, spun down to remove cellular debris and the 
conditioned media was analyzed via Western Blot (A). The change in HMGB1 levels was 
quantified (B) using 72-hour necrotic cells as the reference sample using densitometry. 
Panel A is representative of three blots acquired in three independent experiments.  Panel 
B is quantification of these blots. Data from three independent experiments, ***P<0.001. 
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Figure 3.10A 
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3.5 Assessing the status of HMGB1 in the media post phagocytosis 
 
Having established that HMGB1 is released from dying cells passively over time, we 
postulated that engulfment of both apoptotic and necrotic cells by phagocytic 769P cells 
might enable 769P cells to regulate alarmin levels within its extracellular milieu[271]. 
Correspondingly, we expected that 769P cells that engulf dying cells would have 
increased intracellular content of HMGB1. This has never been shown to our knowledge. 
First, we used KIM-1-PK1 cells and its control pcDNA-PK1 cells to test this hypothesis 
and confirm the preliminary data provided by Dr. Gunaratnam (Figure 1.3). WT-KIM-1 
and pcDNA-PK1 cells were fed live, apoptotic or necrotic thymocytes for 24 hours to 
allow for efficient uptake keeping in mind that KIM-1 phagocytic capacity was not 
saturated during this time period (Figure 3.6). The conditioned medium and cell lysates 
from each cell type fed either apoptotic or necrotic cells were then harvested and 
analyzed by Western Blot for HMGB1 release (Figure 3.11A) and the triplicates were 
analyzed using densitometry (Figure 3.11B). In keeping with our hypothesis, HMGB1 
levels were higher in the conditioned media of non-KIM-1 expressing cells in comparison 
to that of KIM-1 expressing cells. This correlated with a nearly 50% increase in 
sequestered HMGB1 from apoptotic cells in the WT-KIM-1 lysates and a 100% increase 
in the HMGB1 levels from necrotic cells in the same group. Correspondingly, HMGB1 
levels were higher in the media and lower in the lysate of non-KIM-1 expressing cells in 
comparison to KIM-1 expressing cells. Overall, HMGB1 levels from necrotic cells were 
significantly higher compared to apoptotic cells in both the media and the lysate 
regardless of KIM-1 expression. Live cells were not included due to their negligible 
phagocytosis by KIM-1-PK1 cells discussed previously. Importantly, WT-PK1 and 
pcDNA-PK1 cells alone did not secrete significant levels of HMGB1 into their respective 
conditioned media and had lower cellular levels of HMGB1 than their counterparts fed 
either apoptotic or necrotic cells. 
 
The same experiment was repeated in 769P cells pre-treated with siRNA targeting KIM-1 
or control siRNA. First, 769P cells were either untreated or transfected with control 
siRNA or KIM-1 siRNA and incubated overnight. After overnight incubation, equal 
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numbers of apoptotic or necrotic thymocytes were added to the siRNA-treated 769P cells 
for another 24 hours. Thereafter, the conditioned media was analyzed using Western Blot 
for detection of HMGB1. The levels of HMGB1 seen in the conditioned medium of 
siRNA KIM-1 cells fed apoptotic cells (Figure 3.12A) and necrotic cells (Figure 3.12B) 
was significantly higher than what was measured in both the untreated and control siRNA 
treated 769P cells. The levels of HMGB1 seen in the conditioned medium of untreated or 
control siRNA treated 769P cells fed apoptotic cells were comparable. A duplicate 
experiment was done using necrotic cells (Figure 3.12 C and D) and showed that 
silencing of KIM-1 in 769P cells abrogated their ability to limit HGMB1 leak from 
necrotic cells. Once again, there was no statistically significant difference in HMGB1 
release in the conditioned media of either untreated or control siRNA treated 769P cells, 
demonstrating that the findings were KIM-1 specific and not due to non-specific effects 
of siRNA or the transfection reagent. Importantly, there was no detectable HMGB1 in the 
conditioned medium of 769P cells that were not fed any dead thymocytes, confirming 
that any HMGB1 released into the medium was from the dying cells. Also, necrotic cells 
released approximately twice the amount of HMGB1 into the surrounding media 
compared to apoptotic cells.  
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Figure 3.11 Comparison in the leakage of HMGB1 from dying cells after incubation with 
LLC-PK1 cells expressing or not expressing KIM-1. Approximately 1x106 WT-KIM-1 
and pcDNA-KIM-1 cells were plated 24 hours prior and then fed either apoptotic or 
necrotic thymocytes. 24 hours later the wells were harvested and both the conditioned 
media (right panel) and the lysate (left panel) and were analyzed by western blot for 
HMGB1 expression (A). Results are normalized to the actin of WT-KIM-1 and pcDNA-
KIM-1 cells alone.  Panel A is representative of three blots acquired in three independent 
experiments.  Panel B is quantification of HMGB1 within lysate blots 
*** P <0.001 
  
76	  
	  
Figure 3.11A 
 
                   
    Lysate     Media  
Figure 3.11B 
Lysate 
                      
 
 
 
25	  kDa	  
77	  
	  
 
 
 
 
 
 
 
 
Figure 3.12 Inhibition of HMGB1 release from dying cells into the media as a result of 
KIM-1 expression. The same experiment in Figure 3.11 was repeated in Figure 3.12 
except with 769P that were left untreated or treated with control siRNA or KIM-1 
siRNA. After 24-hour incubation with apoptotic or necrotic cells, media samples were 
analyzed via Western Blot for apoptotic cells (A) or necrotic cells (C) Panel A and C are 
representative of three blots acquired in three independent experiments for apoptotic and 
necrotic cells respectively. Panel B and D are quantifications of these blots.  ***P<0.001. 
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3.6 KIM-1 inhibits dendritic cell activation by apoptotic cells 
 
The pro-inflammatory nature of HMGB1 has been well characterized[136]. The 
pleotropic effects of HMGB1 on the innate immune system was outlined in Figure 1.2.  
Based on its ability to induce a strong immune response, it would stand to reason that 
residual HMGB1 in the extracellular milieu resulting from tumours exposed to 
chemotherapy might activate innate immune pathways including dendritic cells. The 
ability to limit such inflammation, for instance via KIM-1 expression (Figure 3.12), 
would be expected to promote cancer survival through enhanced immune evasion. We 
postulated that as a result of the phagocytic clearance of apoptotic cells by KIM-1 
expressing cells, the activation of DCs by HMGB1 released from cells undergoing 
secondary necrosis would be limited[272]. This was tested by feeding WT-PK1 and 
pcDNA-PK1 cells either apoptotic or necrotic thymocytes for 24 hours, and thereafter 
transferring the conditioned medium containing any soluble HMGB1 to activate primary 
DCs [122]. The activation of primary DCs was confirmed by LPS-treatment (10 ng/ml) 
for the same period of time as apoptotic cells and by measuring the percent of DCs that 
expressed CD40 and CD86 on their surface by flow cytometry. Compared to pcDNA-
PK1, WT-PK1 cells were able to reduce apoptotic cell- and necrotic cell-dependent 
activation of DCs by approximately 30% (Figure 3.13).  This experiment was only 
performed once and needs to be reproduced. 
 
A similar experiment was conducted with media from 769P cells transfected with KIM-1 
siRNA, control siRNA, or left untransfected and transferred to dendritic cells. Both 
untransfected or control siRNA transfected 769P cells limited DC activation compared to 
KIM-1- siRNA transfected cells (Figure 3.14). LPS was used as a positive control for 
DC activation as before. Interestingly, DC-activation was increased in the KIM-1 siRNA 
treated population by approximately 30% in comparison to untransfected cells.  
 
One possibility for both 769P and WT-PK1 experiments with dendritic cells is that 
HMGB1 may not be the predominant or sole factor inducing a dendritic cell response. As 
mentioned earlier, the release of HMGB1 can be coupled with nucleic acids or other 
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cellular components that can induce a TLR response in innate immune cells[141]. A way 
to confirm if HMGB1 is a significant player would be to use an HGMB1 neutralizing 
antibody in media samples and see if the same response in dendritic cells to both 769P 
and WT-PK1 cells can be produced.  
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Figure 3.13 KIM-1 expression is sufficient to inhibit the activation of dendritic cells by 
media transfer from uncleared apoptotic and necrotic cells in LLC-PK1 cells. WT-PK1 
and pcDNA-PK1 expressing cells were fed apoptotic or necrotic thymocytes for 24 
hours. The spun-down supernatants were then transferred to primary dendritic cells 
overnight to stimulate their activation. Dendritic cells were then stained with 
fluorescently-conjugated antibodies to detect CD11c, CD40 and CD86. Samples were 
then analyzed via flow cytometry and double positive cells were plotted relative to LPS 
double positive cells. N=1. 
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Figure 3.14 KIM-1 expression is required to limit the activation of dendritic cells by 
uncleared apoptotic and necrotic cells in 769P cells. After siRNA treatment for 24 hours, 
KIM-1 and non-KIM-1 expressing cells were fed apoptotic thymocytes for 24 hours. 
Conditioned media post-phagocytosis was then transferred to dendritic cells overnight 
and samples were then stained for CD11c, CD40 and CD86. Samples were then analyzed 
via flow cytometry and double positive cells were plotted relative to LPS double positive 
cells. Figure 3.14 is N=1 
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Chapter 4: Discussion   
 
4.1.0 Overview  
 
The interplay between the host immune response and the tumour microenvironment 
profoundly influences the clinical outcome of malignancies [4, 108]. Tumours have 
however, developed a variety of intriguing strategies to evade immune surveillance[107]. 
Understanding such mechanisms may lead to novel therapies for human cancer. Recent 
studies have shown that certain cytotoxic chemotherapies induce a form of immunogenic 
cell death in which the release of DAMPs such as HMGB1 from dying tumour cells 
serves as an endogenous adjuvant[124]. Meanwhile, the phagocytic clearance of cell 
corpses has been shown to be immunosuppressive. Here we identified that the PS 
receptor KIM-1, normally found in the injured kidney, is overexpressed by a variety 
human cancers, enabling them to mediate phagocytosis of apoptotic and necrotic cells. 
Moreover, we demonstrated that through expression of KIM-1, human RCC cancer cells 
reduced the release of the DAMP HMGB1 and circumvented the immunogenic effects of 
cell death on DC activation. A model illustrating the potential affects KIM-1 expression 
may have on tumour survival can be seen in Figure 4.1. 
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Figure 4.1 Potential effects of KIM-1 expression on tumour survival. Based on our 
findings that KIM-1 expression can limit the release of HMGB1 from apoptotic and 
necrotic cells, as well as potentially reduce dendritic cell activation, it would stand to 
reason this would influence tumour survival. A decrease in HMGB1 release as a result of 
KIM-1 expression would result in a reduction or abrogation of dendritic cell activation. 
As a result T-cell expansion and recruitment to the site of tumour existence would be 
limited or potentially non-existent. Therefore tumour elimination would be dampened or 
lost, resulting in tumour survival as opposed to destruction. A lack of KIM-1 expression 
would coincide with dendritic cell activation and ultimately tumour destruction.  
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In the first part of the results section we began identifying the expression of KIM-1 on a 
variety of cancer cell lines of lung, renal, prostate, ovarian and kidney origin. Using RCC 
769P cells as a model and porcine epithelial cells expressing KIM-1 as controls, we 
showed that KIM-1 expression in RCC cells converts them into semi-professional 
phagocytes for apoptotic and necrotic cells (Figure 3.9). Next we characterized the 
release of the prototypical alarmin, HMGB1, from live, apoptotic and necrotic 
thymocytes (Figure 3.10). We then examined the ability for KIM-1 expressing cells to 
prevent the passive release of HMGB1 from late apoptotic and necrotic cells. Lastly, we 
revealed that KIM-1 modulated the innate immune response to cell death as it inhibited 
DC activation (Figure 3.14).  
 
4.2.0 Identification of KIM-1 in human cancers 
 
KIM-1 has been largely investigated as a biomarker for kidney injury associated diseases 
such as AKI, lupus nephritis and cardiac dysfunction[273-275]. The high sensitivity and 
consistency of KIM-1 expression- even above traditional markers[276]- has brought 
KIM-1 to the forefront of kidney injury detection and treatment. Although KIM-1-
deficient mice have been generated and have no renal phenotype at baseline [277], their 
response to acute kidney injury has not been reported. Mice expressing a KIM-1 mucin 
domain deletion mutant, rendering it phagocytosis-defective, are normal at baseline 
[278], but have been reported to exhibit severe inflammation and tissue injury after being 
subjected to renal ischemia-reperfusion injury [279]. 
KIM-1 is overexpressed by a number of cancers including renal cell carcinomas[251]. 
KIM-1 undergoes ectodomain shedding[231, 265] and soluble KIM-1 has been proposed 
to be a urinary marker of renal cell carcinoma[231, 250]. In contrast, constitutive KIM-1 
expression in RCC has been examined as a susceptibility gene as well as high levels of 
KIM-1 shedding has been correlated to invasiveness and aggressiveness of tumours 
[250]. Lastly a recent study correlated the expression of KIM-1 to an increase in the IL-
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6/STAT3 growth pathway that may result in growth and angiogenesis of the tumour 
[280]. The association of KIM-1 being either positive or negative with cancer outcome is 
unknown, as most studies are epidemiological in nature. The implication of KIM-1 in the 
pathogenesis of cancer prompted us to investigate a potential role for KIM-1 in the 
regulation of innate immune responses via its phagocytic function.  
Since phagocytosis could only be studied in vitro, we first characterized expression for 
KIM-1 in a variety of cancer cell lines that were available to us. To date, KIM-1 gene 
expression has been reported in renal clear cell carcinomas and ovarian clear cell 
carcinomas, testing negative for numerous other cancers including lung and prostate 
groupings[251]. As a result of our research, we identified high levels of KIM-1 mRNA in 
renal cancer lines (ex. ACHN, 769P, 786-0), a prostate cancer cell line (ex. PC3) and a 
lung cancer cell line (ex. A549) and lower yet significant levels in an ovarian cancer cell 
line (ex. SKOV3) (Figure 3.1). What was interesting to note was that OCC-1 clear renal 
cell carcinoma tested negative for KIM-1, even after studies have shown that tissue 
samples of ovarian clear cell cancers stained 94% positive for KIM-1[251]. Upon 
researching this further, there were as many ovarian clear cell lines that tested positive for 
KIM-1 as there were negative [281, 282]. The discrepancy in KIM-1 expression between 
tumour tissues vs. cell lines may be explained by a tumour microenvironment-dependent 
induction of KIM-1 expression. For example there are many groups who have reported 
both the expression and lack thereof of KIM-1 in cell culture and observed contrasting 
results in clinical samples[252] [250]. 
Ideally, we would have liked to have more thoroughly characterized KIM-1 expression 
by including colorectal cancer cells and some of the ovarian cancers that have been 
confirmed to express KIM-1 to make our applications more exhaustive. In addition to 
recently beginning to characterize the surface expression of KIM-1 in these cancers, 
determining protein levels of KIM-1 in both the lysate and shed into the media would be 
an interesting element to identify further trends between KIM-1 surface expression and 
shedding. We have replicated a substantial amount of our experimental data using 786-0 
cells, but it would be interesting to look at repeating our studies using PC3 or ACHN 
cells that express significantly lower levels of KIM-1 mRNA. Also, we have now 
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established stable cell lines lacking KIM-1 expression in 769P, 786-0 and ACHN cells 
using lentivirus to deliver shRNA-targeting KIM-1, and hope to use these cells in in vivo 
studies in mice to test if the lack of KIM-1 expression affects the ability of these cells to 
form tumours in the presence of an immune system. In order to truly evaluate the 
implications of KIM-1 to the immune evasion of cancers, we need to move toward an in 
vivo model such as the B16 melanoma model in C57BL/6 mice [124]. B16 melanoma 
cells do not endogenously express KIM-1 (Gunaratnam, unpublished observations). To 
this end, we have begun to generate B16 cells overexpressing murine KIM-1 using stable 
transfection. This model has been used effectively to study the immune response to 
cytotoxic chemotherapy-induced cell death[124, 208].     
 
4.3.0 KIM-1 expression confers on RCC cells the ability to phagocytose apoptotic 
and necrotic cells.  
 
A variety of non-professional phagocytes have been shown to possess the ability to 
engulf apoptotic cells including epithelial cells, fibroblasts, hepatocytes and Sertoli cells 
[283, 284]. In fact, epithelial bladder tumours have been shown to phagocytose and 
process damaged red blood cells[285]. In comparison to professional cell phagocytosis, 
non-professional phagocytosis is often regarded to as the secondary or lesser form of the 
two, only playing a noticeable role in the absence or defective nature of professional 
phagocytes[160, 286]. Kidney epithelial cells however are avid phagocytes of apoptotic 
cells[117]. Our goal here was to characterize the capacity for renal cancer cells to 
phagocytose either apoptotic or necrotic cells in a KIM-1 dependent fashion. KIM-PK1 
cells provided a positive control to test our hypothesis as a lack of a response in 769P 
cells may have been indicative of a lack of the phagocytic signalling machinery in RCC 
cells. Accordingly, the LLC-PK1 cells expressing KIM-1 and its counterpart, pcDNA-
PK1 cells, exhibited expected results in our tumour cell model. The strong and 
comparable phagocytic capacity between WT-PK1 and 769P cancer cells demonstrates 
effective expression and signalling of KIM-1 in 769P cells (Figure 3.7). KIM-1 
expression in WT-PK1 cells resulted in more than twice an increase in phagocytosis of 
both apoptotic and necrotic cells. Furthermore, the lack of KIM-1 expression in both the 
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pcDNA cells and 769P cells with KIM-1 knockdown demonstrated the necessity of KIM-
1 expression for phagocytosis of dying cells. Admittedly, the inhibition of phagocytosis 
was not complete with siRNA treatment and likely reflected the incomplete knockdown 
of KIM-1 in these cells. Yet, the near 60% reduction in phagocytic uptake of both 
necrotic and apoptotic cells in 769P cells was mirrored by the 60% inhibition of KIM-1 
expression with siRNA treatment. Taken together, these data showed that KIM-1 
phagocytosis plays a significant role in the ability for renal cells to phagocytose. 
However, without complete inhibition of KIM-1 expression in these cells we cannot rule 
out whether 769P cells employ mechanisms independent of KIM-1 (e.g. other PS 
receptors) to mediate efferocytosis.  
In contrast, what was interesting to note was that only 44% of WT-PK1 cells stained 
positive for KIM-1 where 96% of 769P cells stained positive for KIM-1. This resulted in 
nearly identical capacities for phagocytosis of the same number of cells by both PK1 and 
769P cells. Considering both of these cell types are of epithelial cell origin[287, 288], this 
would imply that the WT-PK1 cells are more efficient at phagocytosing apoptotic or 
necrotic cells.  To address this, we are currently testing 769P and WT-PK1 cells for their 
ability to engulf PHrodo stained apoptotic and necrotic cells in a time- and dose-
dependent manner to test their maximum capacity for phagocytosis of apoptotic and 
necrotic cells  
One of the limitations of our data is that we used dying thymocytes, rather than dying 
cancer cells as phagocytic targets. The rationale for this was that we had established 
assays for this. To fully characterize the phagocytosis by RCC cells in the context of 
tumours, ideally we should repeat the described experiments using necrotic or apoptotic 
renal cancer cells. This might be important given that RCC cells are larger than 
thymocytes, and therefore might be less amenable to phagocytic uptake. KIM-1 has been 
shown to effectively phagocytose viruses, gram-positive and gram-negative bacteria on 
epithelial cells accounting for size diversity [289, 290]. Additionally TIM-4, which 
belongs to the same family of genes as KIM-1, is a PS receptor expressed on dendritic 
cells and has been shown to phagocytose apoptotic and necrotic cancer cells [222]. As a 
result of the diverse cells known to be phagocytosed via KIM-1 mediated PS interactions, 
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the phagocytosis of larger cancer cells should not present as an issue.  
Another model that our lab has been exploring is the mouse B16 melanoma model for in 
vivo work. This model can activate both BimS and FADD death pathways to result in 
apoptotic and necrotic cell death via tetracycline[291]. A potential application of this 
model would be to inject mice with either B16 or KIM-1 B16 tumours. Using tetracycline 
to induce either apoptotic or necrotic death, we would then measure the ability for mice 
to clear tumours. By comparing attributes such as the percent of mice that establish 
tumours, the size of the established tumours, the percent of tumours that are cleared and 
the overall health status of these mice, we can infer a role of KIM-1 in tumour 
progression and survival. 
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4.4.0 KIM-1-expressing cancer cells sequester HMGB1 release by apoptotic and 
necrotic cells via phagocytosis 
 
The role of HMGB1 in the context of cancers has been identified as both a tumour 
promoting and tumour-limiting agent. One group examining patient samples of 
individuals with hepatocellular carcinoma found higher HMGB1 expression levels being 
correlated with lower 5-year survival rates in patients[292, 293]. Further studies have 
identified an interaction between HMGB1 and tumour suppressor protein retinoblastoma 
(Rb) limits the growth of breast tumours in vivo[294]. HMGB1 has also been linked to an 
increase in genome stability through telomere lengthening [295, 296] resulting in 
decreased genetic mutations and lower tumour establishment rates.  
In favour of HMGB1 expression as a tumour promoting mechanism, studies have shown 
HMGB1 plays a role in fulfilling the high-energy requirements seen in tumours. HMGB1 
expression has been linked to increased ATP production and pancreatic tumour 
proliferation[297]. Furthermore mitochondrial HMGB1 interaction with the RAGE 
receptor has also been shown to increase ATP production and loss of RAGE expression 
has been shown to prevent tumourigenesis in the skin pancreas and intestine [298-300]. 
HMGB1 secretion has also been linked to enhancing anti-tumour immunity, through the 
promotion of Treg mediated IL-10 production[301]. Additionally inhibition of RAGE-
HMGB1 interactions has been seen to suppress invasion and metastasis[302] and the 
downstream signalling of RAGE-HMGB1 has been linked to VEGF production as well 
as the production of other pro-inflammatory cytokines to induce angiogenesis[303]. 
Therefore the production and secretion of HMGB1 may have either direct or indirect 
advantageous or disadvantageous roles in the survival of tumours through its effect on the 
immune environment.   
 HMGB1 is a DNA-binding nuclear protein released actively by macrophages and 
monocytes[304, 305] or passively during cell necrosis[272]. It has important roles in 
models of non-infectious inflammation, such as autoimmunity, cancer, trauma, and 
ischemia reperfusion injury[306]. Immunogenic cell death-mediated HMGB1 release 
activates dendritic cells and promotes their functional maturation [123, 124, 307] and 
anti-tumour immunity. Tumour cell evasion of immunogenic cell death represents a 
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potential mechanism for avoiding immune surveillance[208, 308, 309].  
Unlike necrosis or cell death caused by certain cytotoxic agents, the passive release of 
HMGB1 from apoptotic cells is highly debated [122, 310, 311]. As demonstrated in our 
studies, live, apoptotic and necrotic cells all were capable of releasing HMGB1, albeit in 
a time dependent manner. The release of HMGB1 from live cells was deemed 
insignificant for the purpose of our study, since most of our end points were 24 hours or 
less when live thymocytes undergo spontaneous apoptosis as determined by positive 
staining with Annexin V (data not shown). We presume that once thymocytes are 
removed from a viable host they immediately, though at a significantly slower rate, begin 
to transition to an apoptotic and necrotic cell state, shown by the eventual release of 
HMGB1 from into their environment. Apoptotic cells, however, began leaking HMGB1 
as early as 8 hours post UV exposure and continued to do so at an increasing rate as time 
progressed. Over time apoptotic cells can transition from apoptosis to secondary necrosis, 
which is characterized by a lack of membrane integrity not found in apoptotic cells[148, 
272]. This is supported by the Annexin V and PI staining profile of late apoptotic 
cells[312]. Accordingly, we observed a rapid increase in HMGB1 release from 8 hours to 
24 hours, ultimately matching HMGB1 release by necrotic cells at 72 hours. In contrast, 
HMGB1 release from necrotic cells was immediate and persistent over 72 hours. It 
remains to be tested if HMGB1 release from apoptotic and necrotic 769P RCC cells is 
comparable to that of thymocytes. Delayed release or sequestration of HMGB1 from 
dying tumour cells might serve as a novel mechanism of immune evasion and resistance 
to chemo/radio-therapy[123].  
Having characterized the release of HMGB1 from dying cells we determined if KIM-1 
expression by RCC cells would circumvent the passive release of HMGB1 from late 
apoptotic and necrotic cells.  We found that HMGB1 levels in the conditioned media of 
KIM-1-PK1 cells was significantly lower than pcDNA-PK1 cells fed apoptotic or 
necrotic cells. A corresponding increase in HMGB1 levels was present in the lysates of 
cells expressing KIM-1 suggesting that it was sequestered there. Because only 
extracellular HMGB1 is immunologically active[272],  we examined the conditioned 
media for HMGB1 release  in 769P cells fed apoptotic or necrotic cells (Figure 3.12). A 
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paralleled response in HMGB1 release in 769P cells confirmed our prediction that 769P 
cell circumvented HMGB1 release from dying cells. Moreover, the recovery of HMGB1 
in the extracellular compartment after silencing KIM-1 expression suggested a causative 
role for KIM-1 in this process. Despite concluding that KIM-1 expression is necessary for 
preventing the release of HMGB1 from dying cells, we are unable to confirm if this was 
mediated by corpse engulfment. We can merely associate KIM-1-dependent phagocytosis 
of apoptotic and necrotic cells by 769P cells with their ability to limit HMGB1 release 
into the surrounding environment. The absence of HMGB1 in the conditioned medium of 
769P cells cultured in the absence of dying cells ruled out the possibility that the 
observed HMGB1 in the media was released by 769P cells. The reversal of HMGB1 
sequestration by 769P cells by pre-treating the cells with cytochalasin D that inhibits 
actin polymerization (and phagocytosis) would argue that corpse engulfment was the 
mechanism limiting HMGB1 levels in the extracellular milieu by 769P cells. An 
alternative possibility is that HMGB1 could be released by dying cells into the 
surrounding media and that KIM-1 could bind to and phagocytose HMGB1 directly. 
There is no support in the literature however, that KIM-1 can interact with HMGB1 
either directly or indirectly. To confirm one way or another, we could do a co-
immunoprecipitation for HMGB1 and KIM-1 to determine if any interaction between the 
molecules exist.  
It would be interesting to determine if as a consequence of phagocytosis of dying tumour 
cells, cancer cells that express KIM-1 also sequester tumour antigens from reaching 
antigen-presenting cells. As a result, KIM-1-expressing tumours would not only limit 
HMGB1-mediated activation of innate immunity, but also activation of tumour antigen-
specific T-cells by antigen presenting cells [131].  
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4.5.0 KIM-1 expression may help cancer cells evade the innate immune response to 
apoptotic and necrotic cancer cells 
 
Having established that KIM-1 expression on RCC cells is both sufficient and necessary 
for phagocytosis of apoptotic and necrotic cells, and determining that KIM-1 is necessary 
in repressing alarmin release from dying cells, we evaluated whether KIM-1-expressing 
cells could alter the immune response to immunogenic cells death (i.e. cell death 
resulting in HMGB1 release). The induction of inflammatory and immune responses by 
HMGB1 is mediated by expression of TLRs and various pattern recognition receptors 
expressed for instance by DCs. We evaluated the ability for KIM-1 expressing 769P cells 
to prevent DC activation by late apoptotic and necrotic cells. KIM-1 expression in 769P 
cells resulted in impaired expression of the activation markers CD40 and CD86 on 
CD11c-positive primary mouse dendritic cells compared to control siRNA-treated cells 
or LPS control treated cells. These results are, however, premature and require 
confirmation. If confirmed, these data would imply that as a result of phagocytic 
clearance of apoptotic and necrotic cells, cancer cells could limit the immunogenicity of 
dying cancer cells mediated by HMGB1 release into the tumour microenvironment.  
4.6.0 Future Directions  
 
The next step for this project is to move the project in the direction of an in vivo study. 
We have yet to identify mouse cell lines that express KIM-1 endogenously and as a result 
we would have to establish stable KIM-1 mouse cancers. During the course of this 
project I used CT26 mouse colon cancers and transiently transfected them with mouse 
KIM-1. We observed a substantial increase in the phagocytosis of both apoptotic and 
necrotic cells. We did encounter difficulty however, in establishing and characterizing 
stable or high expressers of mouse KIM-1 via western blot. A lab member has been 
working for the past year on the same model and has found the incorporation of KIM-1 in 
CT26 cells to be at extremely low levels. As a result using cell lines that have been 
shown to establish tumours well and transfect easily, and be used frequently in vivo- like 
the E0771 breast cancer cell line.  
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4.7.0 Implications 
 
Kidney cancer represents the eighth most common type of cancer in the world, with over 
90% of cases being of RCC origin. As mentioned previously RCC is highly resistant to 
chemotherapy, resulting in a 95% fatality rate in metastatic conditions[294]. Drug based 
approaches that induce direct tumour cell killing seem to be ineffective begging the 
question if RCC cells are resistant to chemotherapeutic cell death. In the last decade or 
so, the paradigm surrounding cancer treatment has shifted from direct killing to using the 
immune system activation to kill tumours. This principle is founded on the idea that the 
immune system is the most capable agent in tumour killing, as it does it on a daily basis 
as part of its immune surveillance function. Examples of this include the ideas of tumour 
vaccines or activating dendritic cells towards tumour epitopes and then reintroducing 
them back into the affected host.  
The role for anti-KIM-1 therapies in tumour eradication would be used as a means to 
“unmask” the tumour to dendritic cells and the innate immune system so that they can 
effectively remove cancer cells. Knowing that KIM-1 can sequester danger signals and 
potentially antigens, knocking down KIM-1 expression would unveil tumours before they 
are able to outrun the immune system. Therefore KIM-1 may be a potential therapeutic 
target that can help circumvent the resistivity of renal cancers to chemotherapy by 
potentially enhancing tumour immunogenicity, and potentially improve patient survival 
rates.  
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Appendix I: Structure of hKIM-1. Animation of human KIM-1 including the PS binding 
domain located within the Ig head. Structural features include an O-linked glycosylated 
mucin domain as well as a transmembrane and cytoplasmic domain. The blue arrow 
represents the potential cleavage site for soluble KIM-1.  
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Adapted from  Freeman et al., 2010[222] 
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Appendix II: Gating strategy for WT-PK1 and pcDNA-PK1 cells. WT-PK1 and pcDNA-
PK1 cells were fed CFSE stained apoptotic or necrotic thymocytes and allowed to 
phagocytose for .5 hours, 1 hour, 2hours, 4 hours, 6 hours and 24 hours. 10,000 events 
were collected and below represent the applied gating strategy for (A) WT-PK1 cells fed 
apoptotic thymocytes, (B) WT-PK1 cells fed necrotic thymocytes (C) pcDNA-PK1 cells 
fed apoptotic thymocytes and (D) pcDNA-PK1 cells fed necrotic thymocytes.  
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Appendix III: MFI for WT-PK1 vs. pcDNA-PK1 phagocytosis of apoptotic and necrotic 
cells. Representative Median Fluorescence Intensity (MFI) of the phagocytosis of CFSE 
labeled apoptotic and necrotic thymocytes by WT-PK1 and pcDNA-PK1 tubular cells via 
flow cytometry. Error bars calculated based on three replicates and calculations done by 
Flow Jo software 
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